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CHAPTER 1 
General introduction 

COLORECTAL CANCER 
Incidence and Pathology 
Carcinoma of the large bowel affects approximately one person in the 20 in most of 
the Westernized countries [1]. In the Netherlands it is the leading cause of cancer 
related death in women, and second in men. The Dutch cancer Registry registered 
7684 new cases (3927 women and 3757 men) of colorectal cancer in 1991 [2]. The 
incidence of colorectal cancer in the Netherlands ranks second on the list of 
malignancies in women and third in men [3]. Worldwide, the annual incidence rates 
vary widely, from 3.4 in Nigeria to 35.8 cases per 100,000 in Connecticut [4,5]. The 
age-specific incidence of this disease appears to rise steadily from the third decade 
till the end of life. Both sexes are equally represented. 
The etiology of colorectal cancer is unknown, but it is likely that multiple factors play 
an important role in the process of neoplasm development. It has been postulated 
that colorectal cancer is caused and promoted by dietary factors that affect the 
enteric environment [6-8]. Limitation of fat intake and consumption of large volumes 
of fibers are suggested to lower the incidence [9,10]. 
Several heritable syndromes are associated with adenomatous polyposis and a high 
risk of of large bowel cancer [11]. The most important is the familial adenomatous 
polyposis syndrome. People affected with this condition will develop colorectal 
cancer at a young age and 80% of them will have at least one adenocarcinoma at 
the age of 40 years [12,13]. The syndromes of Gardner or Peutz-Jegher are further 
examples of genetic risk factors for colorectal cancer. In addition, there exists a well-
recognized enhanced risk of colonic cancer in patients with inflammatory bowel 
disease, which is related to the onset, severity and duration of the latter disease 
[14,15]. For the majority of colorectal cancer patients, those with the so called 
sporadic disease, there is also evidence of an increased incidence in family 
members [16]. The relatives have a twofold to threefold greater chance of 
developing large bowel cancer than the general population. Therefore, it seems 
likely that the etiology of colorectal carcinoma lies in a subtle interplay of environ-
mental and heridity factors. 
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Most malignant colon tumors start out as small polypoid lesions. These lesions may 
grow into the lumen or into the bowel wall. After the initial mucosal growth, the tumor 
usually first protrudes into the lumen. Subsequent lateral invasion appears to be 
greater in the transversal than in the longitudinal direction, which leads to 
circumferential growth. As the tumor invades through the muscularis mucosae into 
the submucosa, it is termed invasive. 
The lymphatic involvement increases with local tumor grade. The earlier conclusion 
of the pathologist Dukes that lymph node metastases only occur when the local 
tumor has grown into the peripheral tissues is incorrect: up to 20% incidence of 
lymph node metastases is demonstrated in cancer limited to the bowel wall [17]. 
Adenocarcinoma is the most frequent histologic type of colon cancer. It accounts for 
90-95% of all colon cancers [18,19]. 
Over the last half century, several surgical-pathological systems have been 
developed to characterize the stage of the tumor, which remains the most important 
factor for predicting the eventual outcome in the individual patient. The choice of 
adjuvant therapy depends on tumor classification. In addition, the systematic use of 
one and the same staging system would allow a better comparison of the multitude 
of studies on different series of patients which appear in the literature. The most 
widely used systems are the Dukes classification [20] and the TNM (Tumor-Node-
Metastasis) classification [21]. The system which Dukes originally developed in 1932 
for pathological classification of rectal carcinoma describes three stages; A - growth 
limited to the rectal wall, В - extension of growth to perirectal tissues without 
metastases, С - metastases in regional lymph nodes [20]. Later the original Dukes 
classification was modified by Kirklin [22] and Astler-Coller [23]. Most modifications 
have led to confusion and an inability to compare various studies. The main 
disadvantage of the Dukes staging system is that it does not consider the histolo­
gical grade of the tumor, its exact penetration through the bowel wall and the 
number of lymph nodes involved [24,25]. In this respect, the TNM system appears 
the most appropriate staging system because it is simple, considers the number of 
positive nodes as the most important prognostic factor and tumor penetration is 
more exactly defined. However, the Dukes classification remains by far the most 
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widely used. 
Surgical Treatment 
Treatment strategies for potentially curable colorectal cancer are primarily surgical, 
en-bloc resection being the treatment approach of choice. It requires an adequate 
amount of normal colon proximal and distal to the tumor. Because colon tumors 
metastasize to the regional lymph nodes, lymphadenectomy is also performed 
routinely. The extent of lymph node removal remains a topic of debate. Resection of 
central lymph nodes requires ligation of main vascular trunks and therefore results in 
a larger, more risky operation. However, most surgeons consider adequate 
dissection of regional lymph nodes part of effective cancer therapy. 
The extent of resection of the tumor and regional lymph nodes will depend on the 
localisation of the tumor in the colon, the operative findings and the overall medical 
condition of the patient. 
At least 90% of the patients with Dukes A colorectal cancer are cured by surgery 
alone. Muscle wall invasion (Dukes B1) decreases the 5-year survival rate slightly to 
80% and even transmural penetration (Dukes B2) is still associated with survival in 
the range of 6 0 % to 80% [26,27]. However, in node positive patients (Dukes C) 5-
years survival will drop till 20%-40%. In these patients, which represent which repre­
sent 30% [28] of the total patient population presenting with colorectal cancer, will 
not be cured by surgery alone and adjuvant chemotherapy therefore is highly 
indicated. It can be considered standard in Dukes С colonic carcinoma. 
Possible mechanisms of surgical treatment failure comprise: (a) foci of neoplastic 
cells dislodged from the lateral resection margins and lymfatic channels or present in 
venous blood may disseminate as micrometastases; (b) tumor cells may disse­
minate into veins during surgery as a result of manipulation; and (c) intraluminal cells 
exfoliated at the site of bowel transsection or on mucosal margins may lead to 
anastomotic recurrence. 
Local recurrence is a major cause of morbidity and mortality following surgery for 
colorectal cancer [29,30,31]. Local recurrence rates vary widely (4-30%) and are 
probably due to incomplete excision of tumor at the cirumferential resection margin 
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[32,33]. Therefore, the surgical technique of total mesorectal excision is practised to 
clear all the potential tumor tissue [34]. 
The liver is the site of hematogenous metastases. One-third of the patients suffers 
from liver metastases on initial diagnosis and it appears to be the first site of release 
for 40% to 50% of the patients with operable disease [35,36]. From the patients with 
liver metastases only 5% are suitable candidates for surgical resection of these 
metastases [37]. 
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CHEMOTHERAPY FOR COLORECTAL CANCER 
Introduction 
In general, safe and effective adjuvant therapy would be highly desirable in patients 
with Dukes' С colon carcinoma, which comprise 30% of the population presenting 
with colorectal cancer. Trials for adjuvant chemotherapy for colorectal cancer began 
in the 1950s [38,39]. Reviews which cover current treatment approaches and results 
of controlled trials appear regularly [40,41,42,43,44,45]. 
For more than 30 years, 5-fluorouracil (5-FU) has been the mainstay of therapy and 
today it remains the most effective single agent in the treatment of this disease. 
5-Fluorouracil 
Heidelberger and colleagues rationally designed the fluorinated pyrimidines as 
inhibitors of thymidylate synthase [46]. The impetus for the synthesis came from the 
observation that radiolabeled uracil is more avidly utilized by rat hepatomas than by 
non-malignant tissues [47]. This finding implied that the enzymatic pathways for 
utilisation of uracil differ in malignant and normal cells. This difference was used for 
creating a drug with antitumor activity. 
6-fluorouncl « O H i Ç / - 0 ^ Η 0 ^ 5 / ~ ° " \ Ι 
OH Η ОНОН 
б-fluofodeoxyuridlne 5-fluorouridine 
Figure 1: Structure of 5-fluorouracil and its nucleosides. 
The chemical structure 5-FU and its nucleosides is shown in figure 1. 5-FU is an 
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analogue of the naturally occurring pyrimidine uracil with a fluorine atom substituted 
at the 5 carbon position of the pyrimidine ring in place of hydrogen. The presence of 
fluorine does not interfere with the metabolism of 5-FU via the pyrimidine pathway. 
Thus, the anabolic pathways of 5-FU are essentially the same as those used by 
uracil. 
Figure 2. The anabolic metabolism of 5-fluorouracil in humans 
1, undine (thymidine) Phosphorylase, 2, undine kinase, 3 (deoxy)undine monophosphate kinase, 4, 
(deoxy)undine diphosphate kinase, 5, orotidine monophosphate phosphonbosyltransferase, 6, ribonu-
cleotide reductase, 7, thymidine kinase, 8, thymidylate synthase, 9, deoxyundine triphosphate 
diphosphohydrolase, 10, thymidine monophosphate kinase, 11, thymidine diphosphate kinase, 12, 
RNA polymerase, 13, DNA polymerase alpha FdUrd = 5-fluoro-2'-deoxy-undine, FdUDP = 5-fluoro-2'-
deoxyundine-5'-diphosphate, FdUTP = 5-fluoro-2'-deoxyundine-5'-tiphosphate, dUMP = 2'-
deoxyundine-5'-monophosphate, dTMP = thymidine-5'-monophosphate, dTDP = thymidine-5'-
diphosphate, dTTP = thymidme-5'-tnphosphate 
There are three pathways by which 5-FU may be anabolised to form cytotoxic 
nucleotides (figure 2). It may be converted to 5-fluoroundine-5'-monophosphate 
(FUMP), either by uridine Phosphorylase and uridine kinase or, directly, by orotidine-
5'-monophosphate phosphonbosyltransferase. The third pathway utilises thymidine 
Phosphorylase and thymidine kinase for conversion of 5-FU to 5-fluoro-2'-
deoxyuridine-5'-monophosphate (FdUMP). The second, direct, pathway seems to be 
the major route for nucleotide (FUMP/FdUMP) formation in colon tumors [48]. The 
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fact that these nucleotides are retained in the cell, due to the presence of the 
charged phosphate group, allows interconversions to other nucleotides such as 5-
fluoro-uridine-5'-triphosphate (FUTP) and 5-fluoro-2'-deoxyuridine-5'-triphosphate 
(FdUTP). It is still not completely understood which nucleotide is ultimately 
responsible for cellular toxicity. Possible mechanisms involve [49,50]: 
(1) Formation of FdUMP with inhibition of thymidylate synthase activity, which blocks 
the conversion of uridine to thymidine, and suppresses DNA synthesis. 
(2) Formation of FdUTP, which may substitute for thymidine-5'-triphosphate (dTTP) 
and be incorporated and subsequently excised from DNA, resulting in damage in 
newly synthesized DNA. 
(3) Formation of FUTP, which may substitute for uridine triphosphate (UTP) in RNA 
and result in RNA dysfunction. 
Clinical results of 5-FU 
Earlier trials using 5-FU yielded disappointing results [38,39]. Given the 
pharmacological understanding at that time and the dose intensity of therapy 
offered, it is not surprising that no major therapeutic impact was observed. 
Subsequent studies demonstrated a 5 to 10% benefit in 5-year survival [51,52]. For 
Dukes С colon cancer a significant improvement in disease-free survival was noted 
[52]. A meta-analysis of phase III randomized control trials showed that there was a 
consistent, though limited, therapeutic effect of fluoropyrimidine [53]. 
The optimal 5-FU treatment for resected colon carcinomas is still subject to many 
studies. Recent efforts have been directed at optimizing its activity by biochemical 
modulation and by varying treatment schedules with respect to dosage, timing and 
route of administration. Ultimate aim is increasing the antitumor activity and decrea­
sing the toxity of 5-FU. 
Biochemical modulation of 5-FU activity 
Without doubt the basic problem in the poor antitumor activity of 5-FU itself is 
resistance of the tumor cells to the agent. Using biochemical modulation the 
mechanism of resistance may be dealt with. Biochemical modulation involves the 
17 
combination of 5-FU with (an)other drug(s) to increase the selective activity by 
pharmacologic manipulation of its intracellular pathways [54]. 
A successful! method of enhancing 5-FU anti-tumor activity is its combination with 
leucovorin. Several laboratory studies have shown that leucovorin, a folate cofactor, 
increases the biologic activity of 5-FU. The stability of the 5-fluorodeoxyuridylate-
thymidylate synthase complex can be maximized by increasing the intracellular 
concentration of reduced folates such as leucovorin [55]. So, as a source of intra­
cellular reduced folates, leucovorin increases and prolongs the competitive inhibition 
of thymidylate synthetase. 
Prospective clinical studies with 5-FU plus leucovorin show a improved response 
rate and also an improvement of patient survival in metastatic colorectal cancer. 
Significant improvements in the objective tumor response was seen in several 
studies [56,57,58,59,60,61]; the overall tumor response rate varies from 18% till 
44% in the 5-FU/leucovorin group compared to the control group, in the 5-FU group 
tumor response varies from 7% till 12% [56,57,58,59]. Significant survival advantage 
was only reached in three studies [56,59,60]. The median survival was 9 months in 
the 5-FU alone group compared to 12.2 in the 5-FU/leucovorin group in the first 
study [56] and repectively 7 months for the 5-FU, 13,5 months for the high dose 5-
FU/leucovorin and 12,5 months for the low dose 5-FU/leucovorin group in the study 
of the Mayo Clinic group [60]. On the other hand several studies reported no 
differences in survival with the addition of leucovorin [57,58,62,63,64]. 
Levamisole is another drug which is used frequently for modulating 5-FU activity. 
Clinical trials [65-69] proved the efficiacy of this combination which is now 
considered as standard therapy for Dukes С colorectal cancer [70]. The important 
most important 5-FU/levamisol study was recently updated with a median follow up 
of 6,5 years [71]; in conclusion: 5-FU plus levamisole reduced the recurrence rate by 
40% (p < 0.0001) and reduced the death rate by 33%(p=0.0007). 
The mechanism of action of levamisole remains elusive, but it is known that it 
potentiates functions of macrophages, lymphocytes and granulocytes, in particular 
when these are suppressed [72]. Another action of levamisole, which might be 
important for its ¡mmunorestoring and anticancer activity, is the inhibition of specific 
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isoenzymes of the alkaline phosphatase group [73]. This seems especially inte-
resting in combination with 5-FU, because alkaline phosphatase lowers the cellular 
retention of its active metabolite FdUMP by dephosphorylation [74,75]. 
The interferons are a group of proteins with antiviral, antiproliferative, immuno-
modulating and differentiating properties [76,77]. They have been found to exert a 
direct cytostatic effect on human colon tumor cells [78,79]. Incorporation of 
interferon in chemotherapeutic regimens was based on the idea that, as a result of 
their high degree of immune specificity, they would effectively eradicate microscopic 
residual tumor. Synergistic action between interferon and 5-FU has been shown 
against different cancer cell lines, demonstrating a 10- to 100-fold increase in 
maximal cytotoxic effect [80-82]. Preliminary clinical studies with interferon and 5-FU 
in patients with metastatic colorectal carcinoma suggest that interferon may enhance 
the effect of 5-FU [79,83,84,85,86,87]. The overall response rate of a total of 417 
patients in 16 phase 2 trials with a regiment of 5-FU/interferon-a was 3 1 % (range 3-
76%)[87]. However despite evidence of drug synergism, the results of clinical trials 
have not provided evidence that modulation of 5-FU by interferon-a results in a real 
therapeutic response in terms of survival improvement. 
Dosaoeof5-FU. 
A dose response relationship has been suggested for 5-FU in colorectal cancer [88]. 
Most commonly applied is the treatment schedule which includes a bolus injection of 
5-FU. Since 5-FU is a drug with a short plasma half-life of 11 minutes and has 
cytotoxic activity mainly against cells in the S-phase, a bolus injection will affect only 
a small proportion of the tumor cells. Thus, there exists a sound rationale for the use 
of continuous infusion of 5-FU, resulting in a much higher dose-intensity and an 
enhanced therapeutic index [89]. However, the maximal dosage of 5-FU is also 
limited by its general toxity and therefore conflicting with the basic premises of 
cytostatic therapy 'more is better1. 
Route of administration of cytostatic drugs. 
Intravenous administration of cytostatic drugs may not allow sufficient penetration 
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into the abdominal cavity. This may be the reason why, in the case of colorectal 
cancer, the agents are not effective enough to kill all the micrometastases, 
especially at the resection site and peritoneal surfaces wich are at high risk for local 
recurrence [90,91]. Therefore, a logical alternative seems to administer the drug via 
the intraperitoneal route. Cytostatic agents given this way are slowly absorbed by 
the peritoneal lymphatics and veins reaching the liver via the portal vein. Studies 
with 5-FU show that high dose intraperitoneal infusion produces substantial levels in 
the portal venous system [92]. It is known that the intraperitoneal micrometastases 
are mainly vascularised by the portal vein. Pharmacological studies show a 
favourable therapeutic ratio for ablation of residual tumor microemboli on peritoneal 
surfaces [93]. After reaching the liver the drug is metabolized extensively and high 
systemic levels are avoided. It is possible to maintain a 2- to 3- log greater concen-
tration in the peritoneal cavity than in the systemic circulation [94]. Intraperitoneal 5-
FU reduces the growth rate of an experimental liver tumor [95] and, in an animal 
model of colon cancer, prevents both peritoneal and hepatic metastasis [96]. 
Clinical studies indicate that the problem of local recurrence and peritoneal seeding 
is underestimated [91] and a prospective trial showed that even a delayed treatment 
of intraperitoneal 5-FU resulted in a highly significant decrease in peritoneal failure 
compared with intravenous 5-FU [97]. A phase I trial of immediate postoperative 
intraperitoneal floxuridine and leucovorin showed a good toleration, without an 
increase in operative morbidity or mortality [98]. Also, the lack of recurrent 
metastases is encouraging. A number of studies using immediate postoperative 
intraperitoneal 5-FU are in progress [98,99,100] and a current EORTC trial (protocol 
40911) has one arm where patients are treated with intraperitoneal 5-FU. 
In an effort to reduce the incidence of hepatic metastasis the efficacy of portal vein 
infusion of 5-FU after resection for colorectal carcinoma has been explored. 
However the clinical results are equivocal since conflicting results have been 
reported. The failure to demonstrate a consistent reduction in the incidence of liver 
metastases suggests that any benefit derived from this treatment approach is 
probably due to the systemic effects of the chemotherapy [101,35]. On the other 
hand, a recent updated analysis of the largest trial of portal vein infusion showed a 
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reduction of both liver metastasis and death at five years [102,43]. 
Intra-arterial infusion of 5-FU has also been used to treat patients with non-
resectable metastases confined to the liver. Experimental investigations have shown 
that metastatic tumor in the liver is predominantly perfused by the arterial route. 
Although response rates to hepatic artery chemotherapy have been reported to be 
higher than response rates to systemic chemotherapy, the advantages in terms of 
survival remain to be proven [103,104]. 
Timing of administration of cytostatic drugs 
Theories of tumor-cell kinetics and drug resistance predict that cancer cells are more 
susceptible to anti-cancer therapy when the tumor burden is small. As a tumor cell 
population increases an ever expanding number of drug-resistant phenotype 
variants develop [105]. Thus agents with only moderate efficacy in established 
metastatic disease may be able to eradicate micrometastases if applied immediately 
after surgery. Numerous animal model studies have demonstrated that a primary 
tumor can inhibit the growth of metastatic deposits and that its removal can increase 
the growth rate of metastases [106]: the shorter the time after operation 
chemotherapy is started, the more complete is the abrogation of accelerated growth 
in distant tumor foci. Thus, for the most effective control of metastases, treatment 
with the maximum tolerated dose of chemotherapy would best be started at the time 
of tumor removal. In addition, the perioperative period is a logical time for adjuvant 
(immuno) therapy since the cellular antitumor immune responses, which are already 
depressed in patients with gastrointestinal cancer, are - transiently - decreased 
further by major surgery [107]. Tumor implantation and growth of metastases in 
animals is enhanced by operation and anesthesia [108]. Altogether, experimental 
data indicate that the efficiency of adjuvant therapy is inversely proportional to the 
time interval between surgery and therapy. Although so far limited information exists 
to support timing decisions in human neoplasms the considerations mentioned 
above strongly support the thesis that treatment with anticancer agents should begin 
before surgery, at the day of surgery or as soon as possible thereafter [109]. 
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As a consequence of the considerations mentioned above and in the preceding 
paragraphs the interest for immediate postoperative intraperitoneal adjuvant 5-FU 
therapy is increasing rapidly [98,99,100]. This raises the question to what extent 
such treatment would affect the healing process in the intestinal anastomosis. 
Wound repair depends heavily on cellular proliferation and may thus be expected to 
suffer from the concomitant administration of drugs which aim to inhibit proliferation 
of tumor cells. It therefore becomes essential to delineate the hazards of 
perioperative 5-FU-based antineoplastic treatment for anastomotic healing and, if 
present, to develop strategies to prevent the negative effects. 
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WOUND HEALING 
Introduction 
Since the earliest beginning of mankind the treatment of wounds has presented a 
challenge to those versed in the healing arts [110]. Wound repair is a extremely 
complex and dynamic process. In order to understand mechanisms of impaired 
wound healing, knowledge about undisturbed wound healing is essential. 
General mechanisms 
All wounds heal by the same biochemical mechanisms [111]. For simplification, 
wound healing has been divided into three distinct, but overlapping phases: 
inflammation, proliferation and reconstruction (figure 3). 
Inflammation 
(day 1-3) 
Proliferation 
(day 3-10) 
Reconstruction 
(day 10 - ) 
bleeding 
thrombocyt degranulation 
humoral cascades 
coagulation 
cell migration 
phagocytosis/debridement 
cell proliferation 
fibroblast activation 
angiogenesis 
matrix production 
synthesis granulation tissue 
matrix turnover 
cell death 
scar tissue formation 
Figure 3: Schematic representation of wound healing 
Upon injury and tissue damage, the early inflammatory phase starts with the 
vascular response. Disruption of blood vessels results in bleeding which has the 
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effect of cleansing the wound. To prevent further blood loss, the affected vessels 
narrow within a few seconds after injury. This vasoconstriction lasts only for a few 
minutes while the leaks are sealed with blood clots. Vasoconstriction is followed by 
vasodilatation reaching a maximum after 10 minutes. In this phase the permeability 
of the capillary walls to blood components is increased and erythrocytes, leucocytes 
and platelets spill out into the wound area. Also, blood plasma escapes into the 
interstitium. The vascular response is controlled by thromboxane A2, released by 
platelets, that constricts vessels and histamine and serotonine, released by mast 
cells, which promote vasodilatation and increase vascular permeability. Activated 
platelets also release a multitude of active substances, including molecules that 
promote cell migration (e.g. growth factors). The activated platelets initiate the actual 
clotting proces. During the clotting process a fine network of fibrin forms around the 
platelet plug. Its purpose is to "catch" solid blood components (e.g. erythrocytes) and 
to form a clot that provisionallly seals the wound. Also, the fibrin gel imposes a first, 
transient, structure to the wound area which can guide the influx of inflammatory 
cells and fibroblasts and act as a scaffold for the construction of granulation tissue. 
Eventually, the fibrin network is degraded by plasmin. 
Within several hours after the trauma neutrophil granulocytes appear in the wound 
area. They are attracted by chemotactic factors as kallikrein, complement C5a and 
leukotriene B4. Neutrophils have the capacity to phagocytose, i.e. engulf and digest 
foreign bodies. They also release enzymes (collagenase, elastase) that degrade -
damaged - connective tissue. Hours after the neutrophils monocytes migrate into the 
wound. Monocytes are attracted by the same chemotactic factors as neutrophils, but 
also by Platelet-Derived Growth Factor (PDGF) and Transforming Growth Factor-ß 
(TGF-ß), substances released by the aggregating platelets. In the tissue monocytes 
undergo phenotypic transformation into macrophages. 
The influx of monocytes and their transformation into macrophages mark the 
beginning of the second phase of wound repair, the proliferation phase, which is 
characterized by angiogenesis and matrix formation. The macrophage plays a key 
role in the orchestration and execution of both the degradative and reparative 
phases of healing [112]. It releases a plethora of biologically active substances, e.g. 
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growth factors and cytokines, which are essential for the propagation of the prolife­
ration phase. Together with the number of macrophages, the number of 
lymphocytes in the wound area increases. Τ lymphocytes also play a regulatory role 
in the repair sequence, presumably by their production of lymphognes [113]. Both 
cell types probably control to a large extent the formation of granulation tissue which 
is composed of newly-formed matrix molecules produced by the fibroblasts. 
From two days after wounding, fibroblasts start to migrate along the fibrin network 
into the wound area - attracted by growth factors, fibronectin and collagen fragments 
- and to divide at a rapid rate. Fibroblasts are essential for matrix production: in fact, 
the number of fibroblasts participating in wound repair is often an indirect measure of 
the development of wound strength [114]. Signals which initiate fibroblast synthesis 
of matrix molecules are, next to high concentrations of lactate and ascoltiate in the 
wound, mediators as TGF-ß produced by macrophages and lymphocytes. The 
newly formed loose connective tissue has a distinct granular appearance and is 
therefore referred to as granulation tissue; next to collagen (see below), which is 
primarily responsible for the restoration of tissue strength, it consists predominantly 
of proteoglycans and fibronectin. Next to their capacity for matrix production 
fibroblasts also produce enzymes capable of matrix degradation, e.g. collagenase 
and gelatinase, both involved in the degradation of fibrillar collagen, and stromelysin 
which is essential to proteoglycan degradation. 
The final phase of wound repair consists of matrix remodelling. At the same rate as 
fresh tissue formation develops, the provisional fibrin network is broken down by 
fibronolysis caused by the enzyme plasmin. Eventually, a dynamic equilibrium arises 
between synthesis and degradation of collagen and the matrix structure changes to 
increasingly resemble the structure of the intact tissue. The stability of the collagen 
fibrils increases by formation of intermolecular crosslinks and tissue cellularity 
diminishes: macrophages and fibroblasts disappear by necrosis and, probably, 
apoptosis (programmed cell death). The reconstruction phase can take months and 
the end result, although comparable in terms of tissue strength, is never completely 
equal to normal tissue: a scar always remains. 
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Collagen 
Collagen is the most important structural protein in the human body. The ever-
extending collagen superfamily of proteins now contains at least 19 proteins formally 
defined as collagene [115], each with its own characteristic structure and tissue 
distribution. Healing wounds contain predominantly the fibril-forming collagene type I 
and type III. Their structural domain consists of a triple helix, approximately 3000 A 
long, formed from three polypeptide (a) chains, each containing about 1000 amino 
acids, that are coiled into a left-handed helix. The three chains are wrapped around 
each other into a right-handed super-helix so that the final structure is a rope-like 
rod. The α-chains comprise of repeating -glycine-X-Y- sequences, where proline is 
frequently in the X-position and 4-hydroxyproline is frequently in the Y-position. The 
latter amino acid is often used to quantify collagen. The triple helix, stabilised by 
hydrogen bridges between the α-chains, is excreted by the fibroblasts into the 
extracellular space where it polymerizes to strong insoluble fibrils. Collagen 
synthesis (figure 4) is a key process in wound repair. Quantification of synthesis and 
analysis of newly-deposited collagen in the wound area are important parameters to 
assess healing. 
During the intracellular synthesis of collagen the native α-chains are subject to 
extensive posttranslational modification. Lysine and proline residues are 
hydroxylated and galactose or both galactose and glucose are added to some of the 
hydroxylysine residues. The hydroxylation reactions are catalyzed by specific 
hydroxylases which need Fe and ascorbate as cofactors and 0 2 and a-ketoglutarate 
as cosubstrates. The procollagen molecule, which consists of a triple helix with both 
C- and N-terminal linear propeptides, is secreted from the fibroblast by means of 
exocytosis through the Golgi complex. Extracellularly, the propeptides are cleaved 
by proteinases and the collagen self-assembles into fibrils. Lysyl oxidase converts 
some lysine and hydroxylysine residues to aldehyde derivatives that form a complex 
series of crosslinks. Maturation of the crosslinks allows the formation of fibrils of 
increasing size and stability which confer growing strength to the healing wound. 
Under physiological conditions, intact fibrillar collagens (like type I and type III) can 
only be cleaved by collagenases, enzymes belonging to the class of matrix 
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Figure 4: Major events in the biosynthesis of collagen. Covalent modifications of the collagen 
polypeptide include hydroxylation, glycosylaton, disulfide bond formation and proteolytic cleavages; 
these occur in a precisely defined sequence in the rough ER, Golgi vesicles and the extracellular 
space. The modifications allow formation of a stable triple-standard collagen helix and also the lateral 
alignment and covalent cross-linking of collagen helixes into 50-nm-diameter collagen fibrils. These in 
turn aggregate to form the collagen fibers. 
I . Synthesis and entry of chain into lumen of rough ER, 2. Cleavage of signal peptide, 3. Hydroxylation 
of selected prolyl and lysyl residues, 4. Adittion of N-linked oligosaccharides, 5. G lycosy la te of 
hydroxylysyl residues, 6. Chain alignment formation of disulfide bonds, 7. Formation of triple helix 
procollagen, β. Transport vescicle, 9. Exocytosis, 10. Removal of N- and C- terminal prosequences, 
II. lateral covalent cross-linking of tropocollagens, 12. aggregations of fibrils. 
From: Molecular Cell Biology, by Darnell, Lodisch, Baltimore 1986 (with permission). 
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metalloproteinases (MMPs). MMPs, which are all involved in extracellular matrix 
degradation, share a number of characteristics [116]: they are secreted as 
proenzymes, depend on Zn for their activity and are inhibited by specific Tissue 
Inhibitors of Metalloproteinases (TIMPs). There are two distinct collagenases: 
interstitial collagenase (MMP-1), which is produced by a variety of connective tissue, 
inflammatory and tumor cells, and neutrophil collagenase (MMP-8). Both enzymes 
have the distinct ability to cleave α-chains at a single site, producing fragments 
approximately 3/4 and 1/4 the size of the original molecule. Once the higher order 
structure is destroyed, many proteases, including other MMPs like gelatinases, can 
degrade the denatured collagen/gelatin substrate. MMPs are abundantly present in 
wounds [117,118]. Tight regulation of their activity is of utmost importance to 
ascertain an equilibrium between degradation of existing, injured tissue and 
accumulation of granulation tissue. 
Intestinal wound healing 
The wall of the intestine is composed of several layers of different tissues (figure 5). 
The mucosa is mainly responsible for the digestive and absorptive functions of the 
intestine. Structurally, the submucosa is the most important layer and forms the 
backbone of the intestinal wall, determining to a large extent its capacity to withstand 
intraluminal pressure. It is made up almost entirely of collagen [119]. The framework 
of the submucosa consists of two arrays of collagen fibers running diagonally around 
the intestinal wall (figure 6). This orientation of the fibers is essential for the flexibility 
of the submucosa and allows adaptation to the various shapes of the intestinal 
lumen by a simple change in the angles between them. 
The strength of the uninjured intestinal wall thus depends mainly on its submucosal 
collagen. This is also true for the strength of intestinal wounds: in the initial phase of 
healing, the strength of intestinal anastomoses depends on the suture holding 
capacity of existing collagen fibers [120]. Subsequently, newly formed collagen fibrils 
must bridge the wound area and restore preoperative strength. Thus, the amount, 
quality and metabolism of collagen in and around the anastomosis determine the 
development of anastomotic strength and are important parameters to assess the 
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progress of repair. The 'collagenous equilibrium', that is the equilibrium between 
postoperative collagen synthesis and degradation, is crucial to successfull healing 
[121]: prolonged imbalance may lead to impaired healing and increased chances for 
anastomotic dehiscence. 
Figure 5: Schematic presentation of the wall of the small intestine, showing the orientation of the musculature 
in the circular and longitudinal layers and that of the coligen fibers in the submucosa. From: Cell Tisssue Res 
1987; 248: 491-497. With permission. 
Figure 6: A scanning electron micrograph showing the collagenous frame work of the submucosa of the rat 
small intestine. From: Cell Tissue Res 1988; 251:117-121. With permission. 
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Almost 200 years ago the seminal principles of intestinal anastomosis were 
described by Larrey, surgeon to the elite guard of the emperor Napoleon [122]: 
" In suturing wounds of the intestine it is necessary to... preserve the lips in exact 
contact... to include within the points of suture the least possible portion of the 
intestinal tube... to keep in view that union is effected by the bowel's own vessels". 
The same principles have been embodied into a simple standard techniques with 
excellent results [123,124,125]. It is generally agreed that inverting anastomoses 
closed with sutures anchored in the submucosa will heal succesfully. However, 
healing of anastomoses can easily be compromised, even under optimal conditions. 
Anastomotic leakage is a most serious complication of gastro-intestinal surgery with 
reported incidence of 0% to 18% and an associated mortality ranging from 10-30% 
[126,127,128]. A multitude of factors is thought to influence anastomotic leakage. 
The occurence of anastomotic leakage appears special in large bowel surgery, this 
in contrast with surgery in the small bowel[129]. 
Much of our current knowledge on wound healing has been obtained from studies of 
skin wounds. Although it seems likely that all wounds heal by essentially common 
mechanisms, an altered physiological environment may cause differences between 
tissues. As a consequence, there appear to exist marked variations between the 
healing of skin and gastro-intestinal wounds. For example, the development of 
wound strength is less strongly affected by malnutrion in colon anastomoses than in 
skin wounds [130]. Also, experimental diabetes severely reduces the development 
of anastomotic strength in the rat intestine but, contrary to diabetes-impaired skin 
wounds, this phenomenon is not caused by deficient accumulation of collagen [131]. 
In addition, the process of collagen synthesis in fibroblasts from colon and skin, 
which is crucial to the restoration of wound strength, appears to be affected 
differently by regulatory compounds [132]. Thus, wounds in skin and intestine may 
react differently and one should exert caution in extrapolating the results from re-
search on skin repair to the healing of other tissues. 
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Parameters of repair in experimental intestinal anastomoses 
Intestinal healing is dynamic and complex process and very hard to study in man. 
Most of our knowledge concerning the basic mechanisms in anastomotic repair, and 
the way they are affected by various conditions and manipulations, stems from 
experimental work. The parameters used for assessing anastomotic strength and 
anastomotic collagen metabolism will be discussed briefly below [for review and 
more references than those mentioned specifically: see 133]. 
Mechanical parameters 
The development of anastomotic strength can be monitored by measurement of 
either the bursting pressure or the breaking strength. The former is a measure for 
the capability of the intestinal wall to withstand increasing intraluminal pressure, the 
latter reflects its resistance to forces exerted in a longitudinal direction. Usually, one 
of these procedures is chosen to assess anastomotic strength. Recently, it has been 
shown in our laboratory that it is possible to perform both measurements 
successively in one anastomosis [134]. 
The measurement of the bursting pressure comprises distension of a bowel segment 
by infusion of liquid until a leak develops: the pressure at which disruption occurs is 
recorded as the bursting pressure. During the first three to four days after operation 
anastomotic bursting pressure remains low. Thereafter, it increases rapidly to values 
well over those observed in uninjured tissue. The bursting pressure is a good 
parameter to monitor anastomotic repair as long as rupture takes place within the 
actual anastomotic area. This normally happens only during the first postoperative 
days when anastomotic strength is low. After this period of early healing the 
anastomosis grows stronger than the adjacent tissue and rupture occurs outside the 
suture line. One week after operation the anastomotic bursting pressure is usually 
higher than that of uninjured intestine. Under adverse conditions the period where 
the bursting site is within the anastomotic area may be extended. 
The breaking strength is measured by applying an increasing force in a longitudinal 
direction to a bowel wall segment. The peak force necessary to induce disruption is 
taken as the breaking strength. The breaking strength of a newly constructed 
31 
anastomosis is only approximately 30% ofthat of the intact bowel wall. Its strength 
declines even futher, reaching minimal values after two or three days. Thereafter, a 
rapid gain in strength takes place. Seven days old anastomoses are stronger than 
newly-constructed anastomoses but still considerably weaker than uninjured 
intestine. As a consequence, during the measurement of breaking strength breaks 
occur in the anastomotic line for an extended postoperative period, which makes it 
suitable as a parameter for actual anastomotic strength for a longer period than the 
measurement of the bursting pressure. 
Thus, the main difference between the course of postoperative bursting pressure 
and postoperative breaking strength is mainly quantitative and appears to be the 
rate at which the values, measured in normal intestine, are approached: bursting 
strength develops faster than breaking strength. Qualitatively, a similar pattern is 
found with both methods. Also, there appear to be no essential qualitative 
differences in the course of anastomotic strength between small and large bowel, 
although there is some evidence that original strength is restored more rapidly in the 
small bowel. 
Parameters of collagen metabolism 
The major collagen types in healty human intestine are type I, type III and, to a 
lesser extent, type V [135]. Quantification of collagen in enteric anastomoses has 
been synonymous to quantification of hydroxyproline, an amino acid unique to 
collagenous protein in most tissues. Anastomotic hydroxyproline concentrations, 
usually expressed on the basis of dry weight, are transiently reduced during the first 
operative week, if compared to concentrations in the intact intestinal wall. This effect, 
which is more explicit in colonic anastomoses than in ileal anastomoses, has been 
taken as evidence for the occurrence of massive collagen degradation. However, 
such changes do not necessarily represent changes in the absolute amount of 
collagen present in the anastomosis. For instance, a decrease in hydroxyproline 
concentration may indeed be caused by loss of collagen, but also by an increase of 
non-collagenous material, e.g. caused by an influx of inflammatory cells and proteins 
into the wound area, or by a combination of both processes. Therefore, 
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measurement of anastomotic hydroxyproline concentrations alone yields little 
information about collagen metabolism. Anastomotic collagen levels may also be ex-
pressed as hydroxyproline content, i.e. the absolute amount of hydroxyproline 
present per unit length of anastomotic segment. Changes in hydroxyproline content 
reflect the results of collagen metabolism more directly than changes in concentrati-
on do, since this parameter is independent of variations in other anastomotic 
constituents. Measurements of anastomotic hydroxyproline content have yielded 
conflicting results with regard to the quantification, or even the occurrence, of 
collagen degradation during the first days after operation. In a series of experiments 
in our laboratory, where the hydroxyproline content of one-, two-, and three-days old 
ileal and colonic anastomoses was compared to that of newly-constructed control 
anastomoses, no significant decrease was observed [Stoop and Hendriks, 
unpublished observations]. In contrast to collagen degradation, the occurrence of 
net collagen synthesis appears undisputed from data on anastomotic hydroxyproline 
content, which rises sharply from three days after operation onwards, more stronger 
in ileum than in colon. 
Since the collagen (hydroxyproline) content represents the net result of collagen 
degradation and collagen synthesis, it does not allow any quantitative conclusions 
regarding the separate processes. In order to draw conclusions on the course of 
postoperative collagen degradation and synthesis the processes should be 
measured independently. 
In vivo collagen synthesis in intestinal anastomosis can be quantified after injection 
of radioactively labeled proline and measurement of its incorporation into collagen. 
Utilizing this method, it was shown that the collagen synthesis in and around 
anastomoses in both small and large intestine was strongly increased during the first 
postoperative week [136,137,138,139]. However, this technique requires 
administration of large amounts of (expensive) labeled proline to living animals. For 
this reason, an ex vivo method was developed within our laboratory to measure 
collagen synthesis in intestinal expiants [140]. The changes in anastomotic collagen 
synthetic capacity measured this way are very similar to those reported for de novo 
synthesis after in vivo labeling [141,142]. It has also been shown that mRNA for type 
33 
I and type III collagen is increased in anastomotic tissue [143]. 
Collagen degradation has been studied to a lesser extent. While the concepts of 
tissue repair describe a certain amount of extracellular matrix resorption to be an 
integral part of the process, available data on anastomotic collagen content indicate 
that anastomotic collagen degradation is probably of limited extent under normal 
conditions. This does not exclude the possibility that localized degradation of 
collagen, e.g. in the immediate area around the sutures, which would not be found 
with this rather insensitive method, profoundly affects wound strength. The 
probability that collagen degradation occurs to some extent can be derived from 
measurements of increased collagenolytic activity in anastomotic extracts [144,145] 
and identification of a specific collagenase in the anastomotic area by 
immunolocalization [121]. Very recently, changing patterns of matrix 
metalloproteinase activity have been demonstrated in anastomotic extracts during 
the first week of healing [146]. 
Finally, it should be mentioned that wound strength will depend not only on the 
quantity, but also on the quality, of collagen fibrils. The strength and mechanical 
stability of the collagen fibrils is based largely on the formation of intermolecular 
crosslinks between the constituent molecules. It is to be expected that the strength 
of healing anastomoses is related to the maturity of the crossiinking. So far, next to 
nothing is known about crosslink formation in intestinal anastomoses. 
Antineoplastic agents and wound healing 
The use of antineoplastic agents in the perioperative period as an adjunct to surgery 
is becoming increasingly important in the treatment of cancer. Advances in the 
development of new agents have led to more aggressive treatment protocols in the 
perioperative period and thus to delivery of these agents during the stages critical to 
wound healing. The, detrimental, effects will vary according to the type of drug used, 
its dose and the timing of drug administration in relation to surgery. While 
experimental data from rodent models show unequivocally that antineoplastic agents 
adversely affect wound healing (see below), no large clinical trials are available so 
their clinical relevance has to be questioned [147]. 
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Several experiments have shown the detrimental effects of doxorubicin (adriamycin) 
on experimental skin healing [148-153]. Single dose doxorubicin(6-8 mg/kg) 
administred to mice up to 42 days before skin wounding till 21 days after skin woun-
ding had significant decreased wound breaking strength[148-153]. The same 
negative effect of doxorubicin was registred on intestinal healing [154], and on bone 
healing [155]. 
Clinically, the effects on wound healing in human breast cancer patients have been 
reported: 71 % women who received neoadjuvant doxorubicin had significant wound 
complications compared to 10% of patients treated by surgery alone [156]. On the 
other hand, no wound complications were reported in a group of patients undergoing 
surgical treatment for soft tissue sarcomas with concomitant administration of 
doxorubicin [157]. 
Alkylating agents (cyclophosphamide) have profound effects on wound healing in 
experimental rodent models [147,158]. However wound healing was not affected in 
a randomized trial for human breast cancer when cyclophosphamide was given daily 
from day -4 to day 5 [159]. 
In addition, experimental evidence substantiates the potential for diminished wound 
healing for vinca alkaloids [147,160], folic acid analogs [147,160] and miscellaneous 
agents(cisplatin) [161,162,163] used in the perioperative period, but limited clinical 
data do not confirm this [164,165,166,167]. It has to be said that dosage and timing 
of chemotherapy varies widely between experimental and clinical settings. Also the 
difference between clinical symptons of disturbed wound healing and disturbed 
mechanical parameters of wound healing in experimental studies is obvious. Thus 
most experimental studies show impairment of wound strength and other objective 
parameters for wound healing. Clinical experience is less negative in this respect, 
but the basic question whether perioperative chemotherapy increases clinical wound 
complications remains open for debate. Prospective clinical trials must be designed 
to provide this information. 
In the final analysis, the decision to use perioperative chemotherapy must be based 
on the potential risks and benefits of such treatment to the patient. 
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AIM OF THE STUDY 
The fundamental processes in intestinal healing and the effects of various 
interventions, related to e.g. the treatment of cancer patients, on anastomotic repair 
are studied extensively in the Department of Surgery of the Academic Hospital of 
Nijmegen [168-172]. The experiments described in this thesis aim to contribute to an 
understanding - and manipulation - of the influence of perioperative 5-FU 
administration on the healing of intestinal anastomoses. 
There exists an ongoing interest in the use of 5-FU to prevent recurrences after 
surgical treatment of colorectal cancer. It has been shown that combination 
chemotherapy with 5-FU and levamisole could improve 5-years survival by one third 
[71]. Standard therapy of a colorectal carcinoma involves surgical resection of the 
tumor and restoration of bowel continuity. Chemotherapy is routinely withheld until 
several weeks after surgery because it is believed generally that early administration 
could disturb the healing process. Disturbed intestinal healing may result in 
anastomotic leakage, which complication leads to great morbidity and mortality. On 
the other hand, early postoperative administration of 5-FU has several theoretical 
advantages and could further improve the survival of patients operated for colorectal 
cancer. 
For this reason we performed experimental studies, using an established rat model, 
to delineate the hazards of perioperative use of 5-FU, alone or in combination with 
other agents, for anastomotic repair. 
The central questions we sought to answer are: 
* How, and to what extent, affects 5-FU, delivered from the day of operation 
onwards, the healing of anastomoses in both ileum and colon? 
* To what extent do drugs like leucovorin, levamisole and interferon-α, which 
are thought to enhance 5-FU anti-tumor activity, add to the effects of 5-FU on 
anastomotic healing? 
* Is it possible to prevent the negative effects of 5-FU by concomitant 
administration of other drugs? 
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Abstract. 5-Fluorouracil (S-FU) remains the mainstay 
for systemic treatment ofcolorectal cancer. In view of the 
increasing interest in pen-operative administration of an-
tineoplastic agents, we have investigated the effects of 
early postoperative 5-FU on the healing of intestinal 
anastomoses in the rat Animals underwent resection and 
anastomosis of both ileum and colon and 5-FU (20 mg, 
kg body weight) was given, either intravenously or in-
Irapentoneally, on the day of surgery and the two subse-
quent days Healing was assessed three and seven days 
after operation Administration of 5-FU led to a reduced 
while blood cell count However, anastomotic strength 
was not significantly reduced at either time point and 
anastomotic hydroxyproline content was not significant-
ly affected We suggest that limited use of 5-FU during or 
immediately after operation does not necessarily affect 
early anastomotic healing in the intestine 
Résumé. Le 5-Fluorouracil (5-FU) demeure la base du 
traitement systémique du cancer colorectal Ьп raison de 
l'intérêt croissant de l'administration péri-opératoire 
d'agents antinéoplasiques, nous avons étudié les effets du 
5-FU post-opératoire précoce sur la cicatrisation des 
anastomoses intestinales chez le rat Les animaux ont 
subi une résection et anastomose à la fois du colon et de 
l'iléon et le 5-FU (20 mg/kg de poids) était donné soit 
intraveineux soit intra-péritonéal le jour de la chirurgie et 
les 2 jours suivants La cicatrisation était étudiée 3 et 7 
jours après l'opération L'administration de 5 FU con-
duit à une diminution du taux des globules blancs. 
Cependant, la force anastomotique n'était pas diminuée 
de façon significative à chaque contrôle et le contenu 
anastomotique d'hydroxyproline n'était pas significa-
tivemenl changé Nous suggérons que l'usage limité de 
5-FU durant ou immédiatement après l'opération 
n'affecte pas nécessairement la cicatrisation anastomo-
tique précoce de l'intestin. 
Although surgery remains the only curative treatment 
modality for early-stage malignant gastrointestinal tu-
mours, survival clearly depends on the extent of disease. 
In a large percentage of surgical patients the stage of 
disease is such that they are at high risk of recurrence [1 ] 
These patients are excellent candidates for adjuvant ther-
apy 5-Fluorouracil (5-FU) has been the mainstay for 
systemic treatment of colorectal cancer and the results of 
recent studies suggest an increased usefulness for 5-FU-
containmg regimens in the management of patients re-
ceiving adjuvant chemotherapy following a complete sur-
gical resection [2] 
It is generally believed that cytostatic agents, adminis-
tered in the pen-operative period, delay wound healing 
and increase the chance of wound dehiscence [3] Animal 
models provide ample evidence to support this notion. 
For instance, we have found that anastomotic construc-
tion during a course of 5-FU. bleomycin and cisplatin 
resulted in an impaired development of wound strength 
[4, 5], possibly as a result of a strong inhibition of colla-
gen synthesis in the wound area [6] As a consequence of 
this belief, adjuvant treatment is typically withheld until 
the surgical wound has healed Still, there exists a strong 
biological rationale for early systemic therapy [7] If the 
tumour cell population increases an even expanding 
number of drug-resistant phenotypes will develop which 
will become more difficult to eracidate [8] Also surgery 
increases chemosensitivity [9] In view of the importance 
of high-dose 5-FU for the treatment of colorectal patients 
[10] and the increasing interest in pen-operative adminis-
tration, we have investigated the effects of early post-op-
erative 5-FU on the healing of intestinal anastomoses in 
the rat 
The efficacy of cytostatic drugs may be enhanced by 
local application Since metastatic or recurrent tumour in 
most gastrointestinal malignancies include the local su-
ture line and the intraperitoneal surfaces (in addition to 
the liver), better cytostatic activity and higher local drug 
levels may be achieved with intraperitoneal administra-
tion than with systemic application in the same doses 
[II] Therefore, we have compared groups which received 
5-FU intravenously and intraperitoneal^. 
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Materials and methods 
Animals Sixty-five male wistar rats, weighing between 211 and 
280 g, were used They were fed a standard diet and allowed water 
ad libitum They were routinely housed with two animals per cage 
AH rats underwent resection with anastomosis of both ileum and 
colon 
The animals were divided into three groups a control group (C, 
η = 20), a group which received 5-FU intravenously (IV, π = 24) and 
a group which received 5-FU intraperitoneal^ (IP, n = 21) In each 
group, ten animals were killed both three and seven days after 
operation The remaining rats died prematurely (Results) 
Drug administration The dosage schedule of 5-FU was calculated 
on the basis οΓ a review of the literature and pilot studies A dosage 
of 20 mg 5-FU kg body weight was chosen, since it was the highest 
intravenous dose which, in combination with surgery, did not result 
in a prohibitive mortality The drug was given immediately after 
operation and once a day on Ihe next two days In the IV group, 
5-FU (2 mg/ml saline) was administered through the vein of the 
penis, m the IP group 5-FU was injected in a concentration of 
0 5 mg/ml saline 
Operarne procedure After an intraperitoneal injection of sodium 
pentobarbital, d midline incision was made and I cm of both small 
and large bowel were resected, at 15 cm proximal to the ileocecal 
junction, and 3 cm proximal to the rectal peritonea! reflection, re­
spectively Continuity was restored microsurgical^ by the construc­
tion of an inverted one-layer seromuscular end-lo-end anastomosis 
with eight interrupted sutures of β χ 0 monofilament materia] 
(Ethilon) The abdomen was closed in two layers with a continuous 
3x0 silk suture for the muscle layer and staples for the skin 
Analìtica! procedures The rats were killed three and seven days 
postoperatively by an overdose of sodium pentobarbital Immedi-
ately before sacrifice, blood was taken for thrombocyte and leuco-
cyte count measurements After opening the abdominal wound and 
identifying the anastomoses, the adhesions were cut as far as possi-
ble without injuring the intestine An intestinal segment with the 
anastomosis in the middle was removed, with the sutures left in 
place This segment was placed m a tensiomcler which provided an 
increasing force The peak force necessary to induce disruption was 
taken as the breaking strength Subsequently, the anastomosis itself 
was dissected out and a 5 mm segment with the suture line in the 
middle was collected for measurement of hydroxyproline, described 
previously [2]. essentially according to Prockop and Udenfned [13] 
Statistical methods are mentioned with the results 
Results 
In the IV group four animals died prematurely, one each 
on day 2 and day 3 and two on day 5 after the operation, 
in the IP group 1 rat died on day 6 All died of anasto-
motic leakage There was no mortality in the control 
group These differences between groups were not signif-
icant 
All animals lost some weight after surgery (Figure 1). 
The animals treated with 5-FU had lost significantly 
more weight than the controls on day 3 (/"=0 002, 
Wilcoxon) No difference was found between the IP and 
IV groups On day 7 only the IV group had a significantly 
lower weight ( P = 0 008, Wilcoxon) than the control 
group 
White blood cell data are given in Table 1 On day 3, 
the thrombocyte count showed no significant differences 
between groups However, the number of circulating leu-
cocytes was significantly lower in both 5-FU groups than 
in the control group. On day 7, the thrombocytes were 
Fig. 1. Changes in postoperative body weight Boxes control 
group, triangles 5-FU intrapcntonally, circles 5-FU intravenously 
Table 1. White blood cell count at death 
Leucocyte counl (109 L) Thrombocyte count (109/L) 
3 days 7 days 3 days 7 days 
С 12 4±19 13 6±4 9 947±350 12451302 
IP 5 I ±2 0 ·* · 109±26 962±356 І046Ц90· 
IV 5 4 ± 2 6 * · · 5 8±1 7 · · 0 0 0 686 + 398 429 ± 136 *··"""> 
С control, IP intraperitoneal. IV intraveneous 
Results represent average values + SD Differences between groups 
were tested for significance using the Wilcoxon test 
Astenx denotes differences between experimental groups and the 
control group Circle denotes differences between IV and IΡ groups 
*, 0 01</>S0 05, · · , 0 01</><0 01, •·*°°°, ρ¿0001 
significantly reduced in both the IV group and the IP 
group, but the IP group showed significant higher levels 
of thrombocytes than the IV group The number of leu-
cocytes was significantly lowered in the IV group com-
pared to both the control group and the IP group 
No significant differences in anastomotic breaking 
strength either in ileum or in colon were found between 
the three groups (Figure 2) In the ileum the average 
breaking strength in the control group increased from 
0 4 7 ± 0 18 N (SD) at 3 days to 1 40 + 0 32 N at 7 days 
after operation Values in the colon were 1 34 + 0 48 N 
and 2 52 + 037 N, respectively Both 5-FU-treated 
groups exhibited a pattern similar to the control group 
In the ileum, the average anastomotic breaking strength 
was lower in the 5-FU groups than in the control group, 
particularly after 7 days, but the differences failed to 
reach statistical significance 
Hydroxyproline was measured both in the control seg-
ments removed at operation, and in the anastomotic 
area There were no significant differences in the hy-
droxyproline content of control segments from the vari-
ous groups (results not shown) The average anastomotic 
hydroxyproline content is depicted in Figure 3 In the 
ileum, the anastomotic hydroxyproline content of the 
control group more than doubled between 3 and 7 days 
after operation, from 106+30 (SD) to 246 + 80 μg/5 mm 
Values in both 5-FU-treated groups were similar at 3 
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ι Newton 
day3 day 7 
Fig 2 Breaking strength of intestinal anastomoses Data are ex 
pressed as average value (n= 10) ± S D Open bars control group 
dotted bars 5 H I intraperitoneally striped bars 5 FU intravenously 
jg / 5mm 
Ileum 
Colon 
day 3 day 7 
Fig 3 Hydroxyprollne content of intestinal anastomoses Data are 
expressed as average value (n = 10) ± SD Open bars control group 
dolled bars 5 FU inlrarxnloneally, striped bars 5-FU intravenously 
days, but 7 days after operation the average hydroxypro-
line content in the 5-FU groups was somewhat reduced as 
compared to the control group but this difference failed 
to reach significance In colonic anastomoses, the in­
crease in hydroxyprohne content from 3 to 7 days after 
operation was less than in the ileum in the control group 
the average value increased from 166 + 32 to 251 ± 8 9 μg/ 
5 mm Both drug-treated groups behaved similarly 
Discussion 
The 5-years survival after surgery for colorectal cancer is 
still disappointingly low Adjuvant chemotherapy will 
possibly improve this outcome The success of adjuvant 
therapy depends on several factors Its effect is related to 
the type of drug, dosage, the route of administration and 
the timing 
5-FU has a long history [14] in the treatment of cancer 
and is still the cornerstone in the adjuvant treatment of 
colorectal cancer patients despite the availability of oth­
er, more aggressive drugs However, the maximal dosage 
of 5-FU is also limited by its general toxity and therefore 
conflicting with the basic premises of cytostatic therapy 
"more is belter' In addition, intravenous administration 
may not allow sufficient penetration into the abdominal 
cavity This may be the reason why the agents are not 
effective enough to kill all the micrometastases especially 
at the resection site and peritoneal surfaces which are at 
high risk for local recurrence Thus it seems reasonable to 
administer the drug via the intraperitoneal route Cyto­
static agents given this way are slowly absorbed by the 
peritoneal lymphatics and veins reaching the liver via the 
portal vein Studies with 5-f-U show that high dose infu­
sion produces substantial levels in the portal venous sys­
tem [15] It is known that the intraperitoneal micrometas­
tases are mainly vasculansed by the portal vein Pharma­
cological studies show a favourable therapeutic ratio for 
ablation of residual tumour microemboli on peritoneal 
surfaces [11] After reaching the liver the drug is metabo­
lized extensively and high systemic levels are avoided It 
is possible to maintain a 2- to 3-log greater concentration 
in the peritoneal cavity than in the systemic circulation 
[16] 
Clinical studies show that the problem of local recur 
rence and peritoneal seeding is underestimated [17], and 
a prospective trial showed that intraperitoneal 5-FU gave 
a highly significant decrease in peritoneal failure com­
pared with intravenous 5-FU [18] 
But all these theoretical benifits of early peritoneal 
administration or other routes of administration, have to 
be weighed against the possible negative effects on intes­
tinal anastomotic healing 5-FU is a antimetabolite and 
acts during the deoxyribonucleic acid synthetic phase of 
the cell cycle the antitumor effect is mediated by the 
inhibition of thymidylate synthetase Thus, early treat­
ment with 5-FU could conceivably interfere with wound 
repair since this process is characterized by high rates of 
cell proliferation 
Indeed, early reports show increased anastomotic dis­
ruption of small bowel anastomoses of the rat after pre­
operative administration of 5-FU [19] If 5-FU was given 
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daily from operation onwards, rat caecal anastomoses 
showed reduced breaking strength between five and sev­
en days after operation [20] On the contrary, injection of 
5-FU directly into the bowel wall adjacent to the newly-
constructed small bowel anastomosis, did not affect 
anastomotic bursting strength, as measured between four 
and 12 days after operation [21] In addition, intraperi­
toneal administration of 5-FU during the first four post­
operative days, in a dose equivalent to that used in our 
present study, had no effect on colonic anastomotic 
strength [22] However, the measurements were per­
formed after 14 days and do not represent the early, most 
critical, phase of healing A very recent study reports that 
daily treatment with intraperitoneal 5-FU from opera­
tion until death did not alTect the strength of three days-
old colonic anastomoses but significantly reduced the 
strength of seven days-old anastomoses [23] Our findings 
show that early administration of 5-FU does not affect 
anastomotic strength, either three or seven days after 
operation In the colon, the anastomotic hydroxyprohne 
content was not reduced This is in agreement with recent 
results from our laboratory which show that collagen 
synthesis in human colon fibroblasts is refractory to 
5-FU [24] Intravenous treatment leads to a more sys­
temic and protracted toxicity than intraperitoneal treat­
ment, which is apparent from the while blood cell count 
In the IV group, four animals died prematurely, while 
surviving rats showed unimpaired healing In the IP 
group, only one animal died However, differences in 
mortality between groups remained non-significant It 
thus seems that post-operative administration of 5-FU 
over a limited period is not necessarily detrimental to 
anastomotic repair This conclusion is supported by clin­
ical data 5-FU is one of the few drugs that has been used 
clinically in the perioperative period no evidence was 
found for increased anastomotic leakage after intra­
venous infusion commencing during or immediately after 
operation [25, 26, 27] The general assumption that anti­
neoplastic drugs, administered from operation onwards, 
will by definition impair wound healing, must probably 
be revised Possibly, the effects will depend on the type of 
drug and even on the tissue in question We suggest that 
the evidence available with respect to early wound repair, 
both clinical and experimental, yields no compelling rea­
sons to exclude the possibility for the limited use of 5-FU 
during or after resection of intestinal tumors. 
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Post-operatíve levamisole may compromise early healing of experimental 
intestinal anastomoses 
JWD de Waard*, Τ Wobbes, BM de Man, С) van der Linden and Τ Hendriks 
Department of Surgery University Hospital Nijmegen PO Box 9101. 6500 HB Nijmegen, The Netherlands 
Seminary There exists growing interest in immediate post-operative local adjuvant therapy after resection of 
intestinal malignancies It is therefore necessary to assess its potential effect on the healing of intestinal 
anastomoses Five groups (n ™ 20) of rats underwent resection and anastomosis of both ileum and colon a 
control group and four experimental groups receiving intraperitoneal 5-ñuorouracil (S-hU), 5-f-U plus 
leucovonn 5-FL' plus Icvamisole or levamisole alone on the day of surgery and the next 2 days Animals were 
killed 3 or 7 days after operation Another three groups (n = 6) of animals were used to compare anastomotic 
collagen synthetic capacity in control rats or rats receiving 5-FU or 5-1-U plus levamisole On the third 
post-operative day, the average anastomotic bursting pressure in the 5-FU levamisole group was reduced by 
36% as Lomparcd with the control group, both in ileum ( Р - 0 0 2 ) and in colon ( / * = 0 0 l ) Values in the 
other groups were similar to those in the control group Anastomotic breaking strength was significantly 
( / > < 0 025) lowered in the ileum from the levamisole group at both days 3 and 7 Anastomotic collagen 
synthetic capacity was strongly reduced in the 5 FU and 5 FU levamisole groups However, there was no 
significant difference between the control group and the four experimental groups with regard to anastomotic 
hydroxyprohnc concentration and content, either 3 or 7 days after operation Thus, limited use of levamisole, 
alone or in combination with intraperitoneal 5-FU, may compromise intestinal healing 
Keywoi^a. anastomosis fluorouracil, intestine, levamisole 
The recurrence rate is high after surgical treatment of col­
orectal cancer This has prompted extensive clinical investiga­
tions into (he use of chemotherapy as an adjunct to surgery 
Unti l now, disappointing results have been obtained despite 
enormous preclinical and clinical research efforts Although a 
meta analysis of its use shows only limited benefit (Buyse et 
ai, 1988), 5-Fluorouracil ( 5 - F U ) remains the most effective 
single agent, and current research aims lo improve its efficacy 
by combinations with other agents (Mayer, 1992, Kemeny et 
al, 1993) A number of studies have confirmed an improved 
therapeutic activity if 5-FU is combined with folmic acid 
(leucovonn) (Mayer, 1992, Kemeny et al, 1993), while the 
combination ol 5-FU with levamisole also attracts con­
siderable attention (Moertel et al, 1990, Stevenson et al, 
1991) Major questions still to be resolved in the treatment of 
patients by surgery and subsequent adjuvant chemotherapy 
include, next to the choice of cytostatic agents, timing and 
route of administration 
Recurrent disease is mainly found in the liver, at the 
operative site and on the peritoneal surface It has been 
suggested that intraperitoneal chemotherapy would be better 
than systemic chemotherapy since it lowers the likelihood of 
systemic complications while being efficient at the sites of 
both local and distant - hepatic recurrences (Cunliffe and 
Sugarbaker, 1989) Intra pen toneal 5-FU reportedly prevents 
hepatic metastasis in experimental colon cancer (Nordlinger 
et ai , 1991) Since the efficiency of adjuvant therapy appears 
to be reduced with increasing lime interval between operation 
and administration of cytostatic agents (Fisher el a!, 1993), 
there arc excellent reasons to start treatment immediately 
after operation (Harris and Mastrangelo, 1991) when the 
tumour burden is small As a consequence, there exists grow­
ing interest in immediate post-operative local adjuvant 
therapy after resection of intestinal malignancies (Sugarbaker 
et al, 1990, Sugarbaker, 1994) A number of studies using 
immediate post-operative intraperitoneal 5-FU are in pro­
gress (Ghmehus and Pahlman, 1992, G r a f et at, 1994) 
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It thus becomes imperative to assess the potential effects of 
such therapies on the healing of intestinal anastomoses 
Administration of cytostatic agents in the perioperative 
period may be detrimental to anastomotic healing Loss of 
strength, particularly in the early phase when strength is 
relatively low, may increase the chances of anastomotic 
leakage, which is a potentially devastating surgical complica­
tion with concomitant high morbidity and mortality Indeed, 
earlier experiments in our laboratory have shown that 
perioperative intraperitoneal combination chemotherapy con­
taining 5-FU, next to bleomycin and cisplatinum, greatly 
reduces anastomotic strength (de Roy van Zuidewijn et al, 
1991) Intraperitoneal 5-FU affects anastomotic collagen syn­
thetic capacity far more severely than intravenous 5-FU 
(Martens et al, 1992α) Daily intraperitoneal administration 
of 5-FU alone from the day of surgery onwards until 
sacrifice after 7 days strongly inhibits anastomotic repair in 
the rat intestine (Graf et at, 1992, de W a a r d et ai , 1995) 
The present study was undertaken to assess if additional 
medication with leucovonn or levamisole would add to this 
negative effect We reported recently that intraperitoneal 
administration of 5-FU alone on the day of operation and 
the next 2 days does not significantly reduce strength in 
expenmental intestinal anastomoses (de W a a r d et at, 1993) 
Since we expected any additional effect of leucovonn and 
levamisole to be more easily observed under conditions in 
which 5-FU alone does not (yet) impair anastomotic healing, 
we limited drug administration to the first 3 days 
Mftteriab and methods 
Animals 
Altogether, I I B male outbrcd Wistar/Cpb W U rats, weighing 
between 200 and 300 g, were used They were housed two 
animals per cage and had free access to water and standard 
laboratory chow (diet A M I I , Hope Farms. Woerden, The 
Netherlands) 
For the measurement of anastomotic strength and hydro*-
yproline content, 100 animals were randomly divided into 
five groups of 20 animals each, a control group a 5-FU 
group, a levamisole group and two groups receiving 5 - Г и 
plus levamisole or leucovonn Within each group, ten rats 
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were killed 3 and 7 days after operation Collagen synthesis 
was measured in three groups of animals (л = 6) a control 
group, a 5-FU group and a group which received 5-FU plus 
levamisole These rats were killed 3 days after operation 
The study was approved by the Animal Ethics Review 
Committee of the Faculty of Medicine, University of 
Nijmegen 
Drug administration 
5-FU (Abie, Netdnya, Israel) was given intraperitoneal^ in a 
dose of 20 mg kg'1 body weight (concentration l m g m l - 1 
saline) This is the same dose we used previously (de Waard 
et al, 1993, 1995) and represents the highest dose which, in 
combination with surgery, did not result in a significant 
mortaht) Levamisole (Janssen, Beerse, Belgium) was given 
orally, by means of a stomach tube, in a dosage of 5 mg kg - 1 
body weight Leucovorin (Cyanamid, Etien-Leur, The 
Netherlands) was administered intravenously m a dosage of 
10 mg kg - 1 body weight All drugs were given once a day, on 
the day of operation and the next 2 days The animals in the 
control groups received intraperitoneal saline daily 
Operative procedure 
After an intraperitoneal injection of sodium pentobarbital, a 
midline incision was made and I cm of both small and large 
bowel was resected at 15 cm proximal to the ileocaecal junc­
tion and 3 cm proximal to the rectal peritoneal reflection 
respectively Continuity was restored microsurgical^ by the 
construction of an inverted one-layer seromuscular end-to-
end anastomosis with eight interrupted sutures of 8 x 0 
monofilament material (Elhicon, Sommerville, USA) The 
abdomen was closed m two layers with a continuous 3 x 0 
silk suture for the fascia and staples for the skin 
Analytical procedures 
The rats were killed by an intraperitoneal overdose of sodium 
pentobarbital After opening (he abdominal wound and iden­
tifying the anastomoses, the adhesions were cut as far as 
possible without injuring (he intestine An intestinal segment 
with the anastomosis in the middle was removed, with the 
sutures left in place This segment was attached to an 
infusion pump Riled with methylene blue-stained saline The 
pressure was raised with an infusion rate of 4 ml mm' 1 and 
recorded graphically Both the bursting pressure, ι e the 
maximum pressure recorded immediately before sudden loss 
of pressure, and the sue of rupture were noted Thereafter, 
the segment was placed in a tensiometer and the breaking 
strength was recorded Thus, both the bursting pressure and 
breaking strength were measured in the same anastomotic 
segment The validity of [his procedure had been confirmed 
in a pilot experiment Two groups of 20 animals were 
operated and killed after 3 or 7 days (л = 10 each) In the 
first group, only the anastomotic breaking strength was 
measured in the ileum, average values were 23 ± 7 (s d ) g at 
day 3 and 128 ± 35 g at day 7 In the second group, measure­
ment of the bursting pressure preceded analysis of the break­
ing strength Still, the breaking strength in this group reached 
similar levels, 19 ± 1 2 g and 127 ± 3 3 g respectively Like­
wise, similar values for the colonic breaking strength were 
found in both groups 
The anastomotic segment was then cleaned from the sur­
rounding tissue and a 5 mm segment with the suture line in 
the middle was collected The samples were frozen immed­
iately and stored in liquid nitrogen until processing After 
weighing, the samples were pulverised and lyophihsed and 
the hydroxyprohne content was measured as described 
previously (Hesp et al, 1984) 
Collagen synthesis was analysed as the ex vivo collagen 
synthetic capacity in intestinal expiants by measuring the 
incorporation of proline into collagenase-digestíble protein 
(CDP), according to a procedure validated before for rat 
intestinal tissue (Martens et al, 1992Л) Briefly, freshly col­
lected tissue expiants of 1-2 mm1, collected from control 
segments removed at operation and from anastomotic tissue 
removed 3 days after operation, were incubated in medium 
containing pHJprolme for 3 h and the radioactivity incor­
porated into total protein was counted Subsequently, in 
order to determine proline incorporation into collagen, excess 
purified collagenase was added The radioactivity in the 
supernatant represents CDP, as a measure of the amount of 
collagen synthesised Subtraction of the radioactivity in the 
CDP fraction from that in total protein yields the incorpora­
tion into non-col la geno us protein (NCP) The relative col­
lagen synthesis (RCS) was calculated with the formula (Peter-
kofsky et al, 1981) thai takes into account the enrichment of 
proline in collagen compared with other proteins 
Relative collagen C D P
 i n f ) e / 
Incorporation is expressed on the basis of sample wet weight. 
DNA (Burton, 1956) content or protein (Smith et ai, 1985) 
content 
Statistical analysis 
Pairwisc com pansons of groups were performed with a Wil­
cox on test using a level of significance of 2a, A, where к is the 
total number of pa invise comparisons 
This way, comparison of the four experimental groups 
with the control group (Figures 1-3) yields a significant 
difference if P<0 025 Comparison of the two experimental 
groups which were used to analyse collagen synthesis with 
the control group (Figure I and Tables I and II) yields a 
significant difference at /*<0 05 
Results 
No animals died prematurely All rats lost weight after oper­
ation In the control group the average maximal weight loss 
was 9% on the first post-operative day Thereafter, animals 
regained weight At day 7, the average body weight was 
106% of weight before operation Rats m all four experi­
mental groups exhibited qualitatively and quantitatively 
similar changes in body weight 
The average anastomotic bursting pressure - a measure of 
resistance to increasing intraluminal pressure - at day 3 is 
depicted in Figure I At this time point, the bursting site was 
always within the suture line 5-FU, administered either alone 
or in combination with leucovonn, did not significantly lower 
the bursting pressure However, if levamisole and 5-FU were 
given simultaneously, the anastomotic bursting pressure was 
significantly reduced by 36%, both in the ileum (P-002) 
and in the colon (/*»0 01) Levamisole alone had no effect 
Ileum Colon 
Heart I Anastomotic bursting pressure after 3 days Bars repre­
sent average values (л = 10, except for control group, where 
n»B) + sd I. Control group. 2. 5-FU group, J 5-FU/ 
leucovonn group 4, 5-FU levamisole group 5. levamisole group 
•Significantly (P<0 025, see Materials and methods) different 
from control group 
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Figure 2 Anastomotic breaking strength Bars represent average 
values (n = 10) + s d 1, Control group, 2, 5-FU group, 3, 5-FU/ 
leucovonn group 4, 5-F U/lcvamisole group, S, levamisole group 
"Significantly (/><() 025, see Materials and methods) and 
+ almost-sigmftcantly (/*<0 03) different Ггот control group 
Figure 3 Anastomotic hydroxyprohne content Bars represent 
average values (n - 10) + s d 1, Control group, 2. 5-FU group, 3, 
5-FU/lcucovonn group, 4, 5 FU/levamisok group, 5, levamisole 
group 
Task I Ex vivo synthesis of collagen and non-collagen protein in ileal anastomoses 
Control group 5-FU group 
Collagen 
d ρ m /total 
dp m μg- | DNA 
d ρ m mg" ' wet weight 
d ρ m mg ' protein 
RCS (V.) 
Non-collagen 
d ρ m /total 
d ρ m μg"l DNA 
d ρ m mg" ' wet weight 
d ρ m mg"1 protein 
36 926 ± 7784 
194 ±30 
595 ± 72 
14 786 ± 1953 
1 02 ± 0 18 
626 155 ±81 428 
3015 ±770 
9697+ 1572 
246 721 ±81 428 
15 053 ±4092' 
115 ±30* 
297 ± 47· 
6819 ± 1292· 
0 73 + 0 10· 
384 147 ±96 986· 
2912 ±716 
7556 ± 1215 
180 250 ±27 049 
5-FUILEV group 
17 325 ±5225· 
126 ±33· 
310 + 41· 
8573 ±1912" 
0 60 ± 0 06· 
522 343 ± 17 2077 
3747 ± 1045 
9419 ±1355 
255 754 ± 48 956 
Expiants from anastomotic tissue were collected 3 days after operation and incubated for 3 h with 
4 5 μΟ of ['HJprolinc Collagen synthesis is expressed as radioactivity incollagcnase-ditjcslible protein and 
as percentage relative collagen synthesis (RCS) Non-collagen protein synthesis is expressed as 
radioactivity m non-collagenous prolan Data represent average values ( + s d) from six animals 
•Significant ( Ж 0 05) difference with the control group 
Table II Ex vivo synthesis of collagen and non-collagen protein in colonic anastomoses 
Control group 5-FU group 5-FU I LEV group 
Collagen 
d ρ m /total 
d ρ m Ιμ%- ' DNA 
d ρ m mg" ' wet weight 
d ρ m mg"1 prolan 
RCS (V.) 
S7 467±20 399 
221 ± 62 
773 ±150 
17454 ±3214 
1 72 ± 0 32 
31 723 ±11491· 
132 ±26· 
429 + 80· 
9490 ± 1997" 
I 29 ± 0 19· 
27 269 ± 7375· 
101 ±22· 
337 ± 58· 
6948 ±2611* 
I 0 4 ± 0 17· 
Non-collagen 
d ρ m /tomi 
d p m a g ' DNA 
d ρ m mg"1 wel waght 
dpm mg"1 prolan 
670 878 ±62 BIB 
2423 ± 794 
9168 ±1597 
198 068 ±41 505 
438 772 ±120 923· 
1902 ±239 
6175 ±723· 
I35 985±I6I9I" 
488 899+64 817* 
1836 ±383 
6267 ±673· 
127 056 ±34 833· 
Expiants from anastomotic tissue were collected 3 days after operation and incubated for 3 h with 
4 SuCioff/Hlprolinc Collagen synthesis »expressed as radioactivity incollagenase-digcsubleprolan and 
as percentage relative collagen synthesis (RCS) Non-collagen prolan synthesis is expressed ss 
radioactivity in non-collagenous protein Data represent average values ( + s d ) from six animals 
•Significant (P < 0 05) difieren« with the control group 
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Control 6 FU S FU/LEV 
Flgwe 4 Collagen synthetic capacity in control and anastomotic 
segments Bars represent average values (/i™6) + sd Ex vivo 
collagen synthesis in control segments removed at operation 
(closed bars) and in anastomotic tissue collected 3 days after 
operation (open bars) 'Significantly (P<0 05) different from 
control group 
At 7 days arter operation the bursting site was always outside 
the suture line Therefore, the bursting pressures measured at 
this time (data not shown) did not represent actual anas-
tomotic strength 
The average anastomotic breaking strength, a measure of 
the ability to withstand longitudinal forces, is shown in 
Figure 2 The breaking site was invariably within the wound 
area both 3 and 7 days after operation At day 3, similar 
values were found in the control, 5-FU and 5-FU/leucovonn 
groups The average breaking strength in both the 5-FU/ 
levamisole and the levamisole group was lower than in the 
control group However, this effect was only significant 
(P= 0 016) in ileal anastomoses in the levamisole group At 
day 7, ileal anastomoses in the 5-FU/leucovonn ( P - 0 018) 
and levamisole (P = 0 025) groups were significantly weaker 
than those in the control group This was almost (P « 0 038) 
the case for colonic anastomoses in the 5- FU /levamisole 
group 
Hydroxyprohne, as a measure of collagen, was quantitated 
in 5 mm segments containing the anastomosis (Figure 3) No 
differences between the control group and the various experi-
mental groups were observed In the control group the hyd-
roxyprohne content increased from day 3 to day 7 by a 
factor of 2 7 in ileal anastomoses and by a factor of 1 6 in 
colonic anastomoses This increase was similar in the animals 
receiving the va nous cytostatic drugs Likewise, no differ-
ences were found for the hydroxyprohne concentrations in 
the anastomotic segments Average hydroxyprohne concent-
rations were 7 0 ± 1 3 and 9 6 ± 1 8 μg mg' ' dry weight in 3-
and 7-day-old ileal anastomoses respectively, corresponding 
values in colonic anastomoses were 9 7 ± 0 7 and 13 8 ± 
I 9μgmg~ I dry weight Similar values were measured in the 
experimental groups (data not shown) 
We also compared the collagen synthetic capacity, meas­
ured ex vivo in tissue expiants, in the control, 5-FU and 
5-FU/levamisole groups 3 days after operation In the cont­
rol group, this was strongly increased in anastomotic tissue in 
comparison with control segments removed at operation 
(Figure 4), 5-fold in ileum and nearly 3-fold in colon In both 
experimental groups anastomotic collagen synthetic capacity, 
calculated on the basis of DNA content, was significantly 
reduced This effect was also evident if collagen synthesis was 
expressed per anastomosis (d ρ m /total) or on the basis of 
wet weight or protein (Tables I and II) Synthesis of non-
collagenous proteins was affected less strongly, particularly in 
the ileum We found no differences between the 5-FU and 
the 5-FU/levamisole groups 
If resection of an intestinal tumour is followed immediately 
by adjuvant chemotherapy, this procedure constitutes a 
potential hazard for the healing anastomosis The present 
results confirm that 5-FU alone, administered on the day of 
surgery and the next 2 days, does not significantly suppress 
the development of anastomotic strength in the first post­
operative week However, levamisole indeed appears to exert 
a negative effect in this respect The strength of the intact 
and anastomosed intestinal wall is largely derived from col­
lagen, the major structural protein in the submucosal layer 
During the first post-operative days wound strength is 
thought to solely depend on the suture-holding capacity of 
existing collagen fibrils (Hogstrom et al, 1985) From app­
roximately 3 days after operation, the anastomosis starts to 
gain strength Restoration of strength to the level of the 
uninjured intestine depends on de novo synthesis of collagen 
In the control animals, the anastomotic collagen synthetic 
capacity is already strongly stimulated after 3 days and the 
anastomotic collagen (hydroxyprohne) content increases con­
siderably between 3 and 7 days after operation, a similar rise 
in breaking strength is observed over the same period 
Administration of 5-FU until day 3 significantly reduces the 
collagen synthetic capacity in the anastomotic area without 
affecting anastomotic strength measured 3 or 7 days after 
operation This indicates that the enhanced collagen synthetic 
capacity, which may be observed as early as 3 h after oper­
ation (Martens and Hendriks, 1991) is not necessary - at 
least not entirely - for retaining wound strength during the 
first post-operative days The fact that the increase between 3 
and 7 days in both anastomotic strength and collagen con­
tent is unimpeded in the 5-FU group means that the collagen 
synthetic capacity is normalised very quickly after cessation 
of drug administration Alternatively, it could be argued that 
the collagen synthetic capacity normally observed in the 
wound area in fact constitutes an overcapacity it is not fully 
used for collagen deposition and a moderate inhibition does 
not necessarily lead to diminished accumulation of wound 
collagen Thus, immediate post-operative chemotherapy with 
5-FU alone, administered for 3 days, appears to be relatively 
harmless for anastomotic integrity However, if the drug is 
given over a longer period anastomotic strength is impaired 
(Graf et al, 1992, de Waard el al, 1995) 
It seems well established that the therapeutic activity of 
5-FU can be improved by biochemical modulation with 
leucovonn (fohmc acid) (Mayer, 1992, Kemeny et al, 1993) 
Graf et ai (1992) recently reported on the effect of simul­
taneous administration of 5-FU and leucovonn on anas­
tomotic healing in the rat colon In this experiment, the 
drugs were given daily until saenfice at day 7 This way, 
5-FU alone reduced anastomotic strength and addition of 
leucovonn does not lead to further detcnoration The present 
expenment where 5-FU administration is limited to the first 3 
days and does not by itself reduce anastomotic strength, does 
not fully support these results Although neither the bursting 
pressure nor the breaking strength of the anastomoses is 
affected by day 3, the ileal breaking strength is reduced 
significantly in the 5-FU/leucovonn group 7 days after oper­
ation This finding precludes the unequivocal conclusion that 
addition of leucovonn to a post-operative regimen of 5-FU 
constitutes no additional hazard for anastomotic healing in 
the intestine and warrants further investigation 
Post-operative chemotherapy with 5-FU and levamisole 
may also be beneficial to a certain class of patients with 
colorectal carcinoma (Moertel et al, 1990, Stevenson et αϊ. 
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1991) Levamisole, ui conjunction with intravenous 5-FU, 
has already been given in a small study o n the first 3 post · 
operative days fol lowing curative surgery for colorectal 
cancer (Windle et al, 1987) Our results indicate that 
levamisole, administered immediately after operation a lone 
or in combinat ion with intraperitoneal 5-FU, may be harm­
ful to the development of anastomot ic strength In particular, 
the bursting pressure o f 3-day-old anastomoses is reduced in 
the S-FU/levamisole group but not in the 5-FU group Also, 
the average anastomot ic breaking strength tn the levamisole 
group is reduced after both 3 and 7 days, though significantly 
s o only in the i leum 
Comparison o f the col lagen synthetic capacity in 3-day-old 
anastomoses yields n o difference between the 5-FU and 5-
FU/levamisoIe groups We have already indicated above that 
at this t ime point anastomot ic strength is probably indepen­
dent o f de novo col lagen synthesis and largely depends o n 
'old' col lagen Degradation o f existing col lagen fibrils, which 
provide strength to the matrix anchoring the sutures, may 
result in loss o f wound strength Al though the anastomot ic 
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The effects of 5-fluorouracil and interferon-α on early healing of 
experimental intestinal anastomoses 
JWD de Waard*, Τ Wobbes, BM de Man, CJ van der Linden and Τ Hendriks 
Department of Surgery, Universi! \ Hospital Nijmegen Nijmegen. The Netherlands 
Sommar? The continuing search for effective adjuvant therapy after resection of intestinal malignancies has 
prompted a growing interest in both immediate post-operative regional chemotherapy and the combination of 
5-fluorouracil (5-FU) and mterferon-a as drugs of choice We have compared the effects of both compounds, 
alone and together on early healing of intestinal anastomoses Four groups (л = 26 each) of rats underwent 
resection and anastomosis of both ileum and colon a control group and three groups receiving intraperitoneal 
5-FU interferon-л or both on the day of surgery and the next 2 days Animals were killed 3 or 7 days (л = 10 
each) after operation in order to measure anastomotic strength and hydroxy proline content The remaining six 
animals in each group were used to study anastomotic collagen synthetic capacity at day 1 Three days after 
operation ileal anastomotic bursting pressure was lowered by V*A> in the S FU inlerferon-a group 
(P = 0 0104) At day 7 anastomotic breaking strength was reduced significantly in ileum (P 00221) and 
colon (/* = 0 0054) of the 5-1-U/interferon ι group and in colon of the inlcrferon-i group (Я-0 0221) Collagen 
synthetic capacity was strongly suppressed by 5-1-U bui not by interferon-i However no differences in 
anastomotic hydroxyprolme content were observed between groups at both days 3 and 7 Thus, post-operative 
u&e of interferon-:! in particular in combination with 5-FU, may be detrimental to anastomotic repair m (he 
intestine 
Keywords, anastomosis, collagen, fluorouracil, interferon-α, intestine 
Despite the high resectabihty rate and general improvement 
in surgical therapy, nearly half of all patients with colorectal 
cancer will eventually die from recurrent disease Candidates 
for post-operative adjuvant therapy are patients at risk for 
disease relapse, as judged by clinical evaluation, surgical 
examination and pathological examination of resection 
specimens In general, safe and effective adjuvant therapy 
would be highly desirable in patients with Dukes' stage B2 
and С colon carcinoma, which constitute 60 70% of the 
population presenting with colorectal cancer 
Over the last three decades numerous studies have shown 
little or no survival benefit, although small but significant 
clinical improvement, from post-operati ve chemotherapy 
using 5-fluoro uracil (5-FU) as the primary agent (Kemeny 
ex al, 1993, Moerlel, 1994) Presently, preclinical and clinical 
protocols aim to increase the activity of 5-KU-based adjuvant 
therapy The optimal manner in which S-FU should be 
administered still remains to be determined There appear to 
be excellent reasons to start treatment immediately after 
operation (Harns and Mastrangelo, 1991) and to administer 
drugs intraperitoneally (Cunlifle and Sugarbaker, 1969) 
Indeed, a survey of ongoing European trials shows 
increasing interest in treatment modalities that include 
immediate post-operative regional chemotherapy (PahIman, 
1995) 
Much effort has also been directed at enhancing the 
activity of 5-FU by drugs such as leucovonn and levamisole 
Recently, the potential of the interferons has been recognised 
in this respect Interferons are a family of multifunctional 
proteins and components of the host defence against viral 
and parasitic infections and malignancy (Sen and Lengycl, 
1992) in vitro studies have demonstrated that each type of 
interferon may interact with fluoropynmidines m a synergistic 
manner to produce cytotoxicity in a va net у of human cancer 
cell lines (see G rem et al, 1995) In phase II trials in patients 
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with advanced colorectal carcinoma the combination of 
interferon-or, plus or minus leucovonn, with 5-FU appears 
to possess higher activity than 5-FU alone (Grem et al, 1991, 
Pazdur, 1991, Wadlcr et a/, 1991) This increased activity is 
the result of biochemical modulation of 5-FU metabolism, 
with both enhancement of the inhibition of thymidylatc 
synthase and alteration of the pharmacokinetics of 5-FU 
being described 
Accepting the hypothesis that immediate post-operati ve 
administration of intcrfcron-a, together with 5-FU, might 
benefit patients after resection of colorectal carcinoma, it 
becomes essential to investigate the potential effects of these 
drugs on early anastomotic healing in the intestine Loss of 
wound strength increases the risk for anastomotic dehiscence, 
which is a most sen о us surgical complication with 
concomitant high mortality and morbidity Previous experi­
ments in our laboratory have shown that penoperative 
intraperitoneal combination chemotherapy containing 5-FU 
severely reduces early anastomotic strength (de Roy van 
Zuidewijn et al, 1991) In addition, daily intraperitoneal 5-
FU alone from the day of operation onwards strongly 
inhibits anastomotic repair in the rat intestine (Graf et al, 
1992, de Waard et at, 1995α) If administration of 5-FU 
remains limited to the day of operation and the first (wo 
post-operative days anastomotic strength is not significantly 
affected (de Waard et al, 1993) In a recent experiment we 
have examined the effects of 5-FU plus levamisole or 
leucovonn on anastomotic healing (de Waard et α/, 19956) 
Here, we de&cnbe our experiments into the effects of a 3 day 
post-operati ve course of interferon-a and interferon-a plus 5-
FU on early healing of intestinal anastomoses in the rat 
Materials and methods 
Animals 
Altogether, 104 male outbred Wislar/Cpb WU rats, weighing 
between 200 and 300 g, were used They were housed with 
two animals per cage and had free access to water and 
standard laboratory chow (diet AM II, Hope farms, 
Woerden, The Netherlands) 
For the measurement of anastomotic strength and 
hydroxyprolme content, 80 animals were randomly divided 
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into Tour groups of 20 animals each a control group, a 5-FU 
group, an interferon group and a group receiving 5-FU plus 
interferon Within each group, ten rats were killed at 3 and 7 
days after operation Collagen synthesis was measured in 
similar groups of animals (n*-6 each in each group) These 
rats were killed 3 days after operation The study was 
approved by the Animal Ethics Review Committee of the 
Faculty of Medicine, University of Nijmegen 
Drug administration 
5-FU (Abie, Netanya, Israel) was gwen intraperitoneal^ in a 
dose of 20 mg kg - 1 body weight (concentration I mg ml - 1 
saline) This is the same dose we used before (de Waard et ai, 
1993, 1995<7,¿>) and represents the highest dose which, in 
combination with surgery, did not result in a significant 
mortality Recombinant rat interferon-a (van der Meide et 
ai, 1986, specific activity 6 x l O * U m g ' protein) was 
administered intraperitoneal^ in a dose of 2x10* U kg ' 
body weight (concentration 2 χ IO3 U ml 'saline) The drugs 
were given once a day, on the day of operation and the next 
2 days The animals m the control groups received 
intraperitoneal saline daily 
Operative procedure 
After an intraperitoneal injection of sodium pentobarbital, a 
midline incision was made and I cm of both small and large 
bowel was resected, at 15 cm proximal to the ileocaecal 
junction, and 3 cm proximal to the rectal peritoneal reflection 
respectively Continuity was restored microsurgical^ by the 
construction of an inverted one-layer seromuscular end-to-
end anastomosis with eight interrupted sutures of 8 x 0 
monofilament material (Ethicon, Sommerville, USA) The 
abdomen was closed in two layers with a continuous 3 x 0 
silk suture for the fascia and staples for the skin 
Analytical procedures 
The rats were killed by an int râpent oneal overdose of sodium 
pentobarbital After opening the abdominal wound and 
identifying the anastomoses, the adhesions were cut as far 
as possible without injuring the intestine An intestinal 
segment with the anastomosis in the middle was removed, 
with the sutures left in place This segment was attached to 
an infusion pump rilled with methylene blue-stained saline 
The pressure was raised with an infusion rate oí 4 ml min"1 
and recorded graphically Both the bursting pressure, ι e the 
maximum pressure recorded immediately before sudden loss 
of pressure, and the site of rupture were noted Thereafter, 
the segment was placed in a tensiomcter, and the breaking 
strength was recorded Thus, both the bursting pressure and 
breaking strength were measured in the same anastomotic 
segment The validity of this procedure has been confirmed in 
a pilot experiment Anastomotic breaking strength was 
compared in two groups of rats, either measured directly or 
after the procedure used for measuring the bursting pressure, 
and found to be similar in both groups (de Waard et at, 
1995/)) The anastomotic segment was then cleaned from the 
surrounding tissue and a 5 mm segment with the suture line 
in the middle was collected The samples were frozen 
immediately and stored in liquid nitrogen until processing 
After weighing, the samples were pulverised and lyophihsed 
and the hydroxyprohne content was measured as described 
before (Hesp et al, 1984) 
Collagen synthesis was analysed as the ex vivo collagen 
synthetic capacity in intestinal expiants by measuring the 
incorporation of proline into collagenase-digestiblc protein 
(CDP), according to a procedure validated before for rat 
intestinal tissue (Martens et ai, 1992) Briefly, tissue expiants of 
1 - 2 mm2, freshly collected from control segments removed at 
operation and from anastomotic tissue removed 3 days after 
operation, were incubated in medium containing ['HJproline 
for 3 h and the radioactivity incorporated into total protein 
was counted Subsequently, in order to determine proline 
incorporation into collagen, excess purified collagenasc was 
added The radioactivity in the supernatant represents CDP, as 
a measure of the amount of collagen synthesised Subtraction 
of the radioactivity in the CDP fraction from that in total 
protein yields the incorporation into non-collagenous protein 
(NCP) The relative collagen synthesis (RCS) was calculated 
with the formula (Peterkofsky et ai, 1981) that takes into 
account the enrichment of proline in collagen compared with 
other proteins 
Relative collagen synthesis (%) = CDP (NCP χ 5 4) 4- CDP χ 100 
Incorporation is expressed on the basis of sample wet weight, 
DNA (Burton. 1956) content or protein (Smith et ai, 1985) 
content 
Statistical analysis 
To correct for the fact that multiple comparisons were made, 
pairwise comparisons of groups were performed (with a two-
tailed Mann-Whitney test) using a level of significance of 
a' = 2a/k, where к is the number of pairwise compensons 
For instance, differences between the three experimental 
groups and the control group (Figures 2-4) were considered 
significant (a = 0 05) at P<*\ where a '= 2 χ 0 05/3 = 0 033 
Resurtí 
No animals died prematurely dunng the expenmental protocol 
Up to 24 h after operation, all rats lost approximately 8% of 
their body weight Thereafter, animals regained weight, 
although clear differences were observed between groups 
(Figure 1) Weight gain in the 5-FU group was significantly 
slower than in the control group Administration of 
J 100 
0 1 2 Э 4 5 6 7 
Days after operation 
Ftgwe 1 Course of body weight Data represent mean values 
(n=IO) and, for the control group only, the sd (O). control 
group, (φ), interferon-a group, (Δ). 5-FU group, (A). 5-FU/ 
interferon-a group Significant differences (P<0 033. see Maten 
als and methods) between groups are denoted by # (interferon-a 
vs control group), * (S FU vs control group) and S (5-FU vs 
5-FU/interferon-a group) 
64 
Fluorouracil, Intarferwt шмі MMBtomotlc healnf 
JWO de Waard et ai fifi 
713 
interferon-а appeared to increase the rale of weight gain over 
the first post-operative days mean body weight was 
significantly higher in the interferon-Œ group than in the 
control group from day 3 onwards and in the 5-FU lnterferon-
α group than in the 5-FU group from day 5 onwards 
Anastomotic strength may be assessed both from the 
bursting pressure, which represents its resistance to 
intraluminal pressure, and from the breaking strength, which 
reflects its ability to withstand longitudinal forces 
Figure 2 depicts the outcome of all measurements of 
anastomotic bursting pressure performed at 3 days after 
operation At this time the bursting site was always within 
the anastomotic area In altogether six (out of 80) 
anastomoses the bursting pressure could not be measured 
because of technical problems Neither 5-FU nor inierferon-a 
administration led to a significant change in bursting 
pressure However, the mean bursting pressure of ileal 
anastomoses in the 5-FU/interferon-a group (44 ± 7 mmHg) 
was significantly (/* = 0 0104) lower than that in the control 
group (70 ±20 mmHg) In addition, it was also significantly 
reduced with respect to the 5-FU group {P=0 0037) and the 
interferon-α group (/> a c0 0062) In colon, these differences 
did not reach statistical significance At 7 days after 
operation the bursting site was always outside the suture 
line and therefore the bursting pressures measured (data not 
shown) did not reflect actual wound strength 
When measuring the breaking strength (Figure 3) the 
breaking site was invariably located within the wound area 
At 3 days after operation no differences were found between 
groups, but after 7 days the breaking strength of both ileal 
and colonic anastomoses was significantly lower in the 5-FU/ 
interferon-! group than in the control group Also, 
anastomotic breaking strength in the colon was reduced in 
the intcrfcron-α group 
The hydroxyprohne content in 5 mm segments containing 
the anastomosis was quant ι la ted as a measure of wound 
collagen levels (Figure 4) No differences between the control 
group and the experimental groups were observed The 
hydroxyprohne content increased similarly from 3 to 7 days 
after operation independent of medication Likewise, no 
differences were found for hydroxyprohne concentrations 
Mean hydroxyprohne concentrations were 7 0 + 1 1 and 
9 6 + 1 8 ^g mg ' dry weight in 3- and 7-day-old ileal 
anastomoses respectively, corresponding values in colonic 
ι 2 Э 4 1 2 3 4 
Day 3 Day 7 
F l g m 3 Anastomotic breaking strength Bars represent mean 
values ( л * 9 or 10) + s d I control group 2 5 FU group 3, 
intcrleron-α group, 4 5-FU/inlerferon-a group 'Significantly 
( / > < 0 033, see Matenals and methods) different from control 
group 
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anastomoses were 9 7 + 0 7 and 13 8 + 1 9 ¿ig mg ' dry 
weight Similar values were measured in the experimental 
groups (data not shown) 
The collagen synthetic capacity, measured ex vtvo in tissue 
expiants, was assayed in control segments removed at 
operation and in 3-day-old anastomotic tissue from the 
same rats Table I shows that in the control group collagen 
synthetic capacity, expressed on the basis of DNA, wet 
weight or protein, was strongly increased in wound tissue 
This increase was significantly {P = 0 0313) higher in ileum 
than in colon The fact that the percentage relative collagen 
synthesis was also elevated indicates that collagen synthesis 
was stimulated to a larger extent than the synthesis of non-
collagenous proteins Figure 5 depicts the anastomotic 
collagen (and non-collagenous protein) synthetic capacity, 
calculated on the basis of DNA content, for the various 
groups Treatment with 5 FU significantly reduced collagen 
synthetic capacity without affecting the production of non-
collagenous protein In contrast, treatment with mterferon-a 
did not appear to affect these processes to any substantial 
degree since no significant differences were seen between the 
intcrferon-a group and the control group or between the 5-
FL' inlerleron-a group and the 5-FU group Similar results 
were obtained if the collagen synthetic capacity was expressed 
on the basis of wet weight or protein content (data nol 
shown) 
Discussion 
The continuing search for effective adjuvant therapy after 
resection of colorectal carcinoma has resulted in a growing 
interest in the efficacy of both immediate post-operative 
regional chemotherapy (see Pâhlman 1995) and the 
combination of 5-r-U with interferon a ¿s the cytostatic 
drugs of choice (see Grem et α/, 1995) The present results 
indicate that caution should be exerted in the use of 
interferon-a as an adjunct to 5-FU therapy in the early 
post-operative period since such treatment might constitute a 
threat to undisturbed anastomotic healing The combination 
of interferon-a and 5-FU, administered lnlrapen toneall y on 
the day of operation and the first two post-operative days, 
reduces the development of anastomotic strength during the 
first week after its construction Administration of 5-FU 
alone has no significant deleterious effect on wound strength, 
but interferon-a in itself significantly lowers strength below 
control values in 7-day-old colonic anastomoses 
The wound healing process is characterised by massive cell 
migration and proliferation Cytostatic drugs are by nature 
antiproliferative and may therefore be expected to interfere 
Increase in anastomotic collagen synthetic capacity 3 days 
after operation 
Ileum 
D p m |ig 
D ρ m mg 
D ρ m mg 
RCS ( % | 
Colon 
D p m № 
D p m mg 
D ρ m mg 
RCS (%) 
DNA 
wet weight 
protein 
DNA 
wet weight 
protein 
Control 
segment 
4 1 + 6 
85 ± 2 4 
2578 + 654 
0 4 7 ± 0 0 a 
8 6 1 1 8 
3 0 5 + 4 5 
7 3 I 7 ± I 0 I 9 
1 I 2 ± 0 I 2 
Anastomosis 
194-130 
595 ± 7 2 
14786 + 1953 
1 0 2 ± 0 I 8 
221 ± 6 2 
7 7 3 ± I 5 0 
I7454±3214 
1 7 2 ± 0 32 
Ratto 
4 9 ± I 2 
7 6 ± 2 2 
6 0 ± I 4 
2 2 ± 0 5 
2 6 ± 0 9 
2 6 ± 0 7 
2 4 ± 0 4 
1 5 ± 0 2 
bxplams from control segments collected at operation, and 
anastomotic tissue collected 3 days after operation, were incubated 
for 3 h with A 5 μΟ of [3H]proline Collagen synthesis is expressed as 
radioactivity in collagenase-digestible protein and as percentage 
relative collagen synthesis (RCS) Data represent average values 
( + s d ) from six animals 
with wound healing Indeed, 5-FU administered daily from 
the day of operation onwards until sacrifice after 7 days 
severely impairs anastomotic healing in the rat intestine (Graf 
et al, 1992, de Waard et al, 19950) In earlier experiments, 
we med to mitigate this negative effect by concomitant 
administration of either interleukin 2 or granulocyte-
macrophage colony-stimulating factor, but 5-FU impaired 
repair was not essentially altered by either cytokine On the 
other hand, retinol significantly promoted 5-FU suppressed 
anastomotic heating (de Waard et al, 1995α) Also, we 
reported before that the negative effect is limited if 5-FU is 
given only three limes (de Waard et al, 1993, 1995α) Since 
we expected any additional effect of interferon-α to be 
observed more easily under the latter conditions, we limited 
drug administration to the first 1 days 
Ê 100 
1 2 3 4 1 2 3 « 
Figm 5 Anastomotic collagen synthetic capacity Bars represent 
mean values (n-6) + sd oí ex vivo synthesis of collagen (a, 
expressed as radioactivity in coJlagcnase digestible protein, с 
expressed as percentage relative collagen synthesis, RCS) and 
other proteins (b. expressed as radioactivity in non-collagenous 
protein) I control group 2 5-FU group 3 inlerferon-i group, 
A. 5 FU inlerferon-a group Differences between groups are 
considered significan! at P<00\1 (see Materials and methods) 
and nearly significant (symbols in brackets) at /*<0 033 * 
significant »r control group S significant vs 5-FL' group, #, 
significant vs interferon a group 
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So Гаг, little is clear about the effects of interferons on 
wound heating Interferon-γ, delivered intrapentoneatly 
through an osmotic pump (Granslein et α/, 1989) or injected 
subcutaneously (Miles et al, 1994), has been found to delay 
skin repair in mice In the latter study, wound disruption 
strength was reduced significantly at a dose of 7 χ 10* U kg - 1 
body weight and higher Two experiments, with opposite 
results, have been reported on the effects of interferon-!*//* on 
cutaneous healing in rodents Intramuscular injection of 
interferon-a/0 or intraperitoneal administration of polyino-
sinic-polycytidyhc acid, a potent inducer of interferon, 
seemingly enhances repair (Bhartiya et at, 1992), while local 
subcutaneous injection of interferon-α//} beneath the wound 
actually inhibits repair (Stout et al, 1993) In these studies, 
evaluation of repair was solely on the basis of macroscopic or 
histological parameters, functional parameters, like wound 
strength, were not reported 
The present study is the first effort to investigate the effect 
of purified interferon-a on wound strength Rat recombinant 
interferon-α was given in a daily dose of 2 χ 10* U kg"1 body 
weight This dose is more than sufficient to protect rats 
against a lethal Pseudorabies virus (PH van der Meide, 
personal communication), but is substantially lower than the 
doses of interferon employed in the studies mentioned above 
Still, daily doses of this relatively low dose of шіегГсгоп-з, 
administered on the first three post-opera live days, signifi­
cant! ν reduce anastomotic breaking strength in the colon 7 
days after operation The results of treatment with the 
combination of 5-FU and interferon-a are probably of more 
immediate interest in terms of potential treatment of patients 
with colorectal cancer It seems clear that addition of 
interferon α to a regimen of 5-FU, which in itself does not 
affect anastomotic strength, may lead to a significant and 
substantial reduction in anastomotic strength during the first 
week of healing In this pen od, where clinically most leakages 
occur, the strength of the anastomosed segment is relatively 
low as compared with the strength of the uninjured intestine 
any further reduction constitutes a threat to anastomotic 
integrity and increases the chances for anastomotic dehis­
cence Thus these data should be treated as a warning that 
clinical application of 5-FU plus inlerferon-cr immediately 
after anastomotic construction, although possibly beneficial 
with respect to adjuvant effectivity, may result in undesirable 
(side-) effects with respect to wound repair 
It remains to be determined how exactly interferon-a 
interferes with the healing sequence The strength of both the 
uninjured and the sutured bowel wall depends to a large 
extent on collagen and anastomotic construction leads very 
quickly to an increased collagen synthetic capacity within the 
wound area (Martens and Hendriks, 1991) Interferons are 
known to be able to inhibit collagen synthesis (Granstein et 
al, 1990) This suppressive effect is well established by in vitro 
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DKK,IN M M i l Κ I I 
Retinol May Promote Fluorouracil-Suppressed 
Healing of Experimental Intestinal Anastomoses 
Jan Willem D de Waard, MD, Theo Wobhes, MD, PhD, 
Cees J van der Linden, MD, PhD, Thijs Hendriks, PhD 
ι To examine the effects of penoperative ad­
ministration oí Fluorouracil on healing venables of in-
testinal anastomoses and to explore ways to promote re-
pair under these conditions 
(toclgai Seven-day, prospective randomized expérimen-
tal trial 
$»НІщі Animal research laboratory 
Двішаім Male young-adult Wistar rats after resection 
and anastomosis of both ileum and colon 
IntervMrtloiui Random assignment to groups receiv­
ing placebo, daily Fluorouracil (20 mg/kg per day, intra­
peritoneal^), daily Fluorouracil plus reiinol palrmlate 
(5000 lU/kg per day, orally), daily Fluorouracil plus ìn-
terleukin-2 (2X106 lU/kg per day, subcutaneously), or 
daily Fluorouracil plus granulocyte macrophage colony-
stimulating Factor on the First 4 days after operation (20 
M-g/kfi per day, intrapentoneally) 
t Anastomotic bursting pres-
sure, breaking strength, hydroxyprolme content, and ex 
vivo collagen synthetic capacity 
••емIUt Administration of Fluorouracil decreased 
anastomotic breaking strength by more than 40% and 
caused a shift in bursting site from outside to within the 
suture line It also lowered anastomotic hydroxyprolme 
content The capacity for collagen synthesis, which was 
greatly enhanced in 4-day-old anastomoses From the 
control group, was significantly (P< 05) and specifi­
cally reduced Concomitant administration of retinol 
resulted in restoration of strength and hydroxyprolme 
content, particularly in the ileum lnterleukin-2 and granu­
locyte macrophage colony-stimulating factor did not 
improve fluorouracil-suppressed repair both wound 
strength andcollagcn content were similar in the fluoro-
uracil, Fluorouracil/inlerleukin-2, and Fluorouracil/ 
granulocyte macrophage colony-stimulating Factor 
groups 
Conclusioni Intraperitoneal administration oF Fluoro­
uracil, delivered from the day of operation onward, 
severely reduces anastomotic strength at the end oF the 
first postoperative week This negative eFFect may be 
prevented by oral administration of retinol 
(Arch Surg 1995,130 959-965) 
From the Department of 
Surgery University Hospital 
Nijmegen (the Netherlands) 
Dr de Waard is currently 
affiliated with the Department 
of Surgery Westfries Gasthuis, 
Hoorn the Netherlands 
I N THE WESTERN world, colorectal cancer is the second most Frequent malignant neoplasm after lung can­cer More than halFlhe pauents with this disease will die of it as a con­
sequence of locoregional or distant spread 
While surgery remains the only curative 
treatment modality for early-stage disease, 
the most important prognostic feature noted 
to date in colorectal cancer is the surgical 
pathologic stage of the tumor resected At 
least 90% to 95% of pauents with Dukes' stage 
A or Bi carcinoma of the colon are cured by 
surgical resection alone However, patients 
with stage B2 disease have a 30% to 70% 
chance of 5-year survival after surgical 
therapy alone, and pauents with stage С dis­
ease haveonlya 10%to50%chance 'Inthese 
patients, who represent 60% to 70% of the 
total patient population presenting with co­
lorectal cancer, adjuvant therapy is highly 
indicated Fluorouracil is the recommended 
standard treatment and has remained the 
building block For adjuvant ι nais 2 
Adjuvant therapy in colorectal can­
cer routinely is withheld until weeks a Fier 
surgery However, there exists an excel­
lent rationale to start therapy in the imme­
diate postoperative penod 1 Theones of tu­
mor-cell kinetics and drug resistance predict 
that cancer cells are more susceptible to an­
ticancer therapy when the tumor burden is 
small1 Numerous animal model studies 
have demonstrated that a pnmary tumor can 
See Materials and Methods 
on next page 
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MATERIALS AND METHODS 
ANIMALS 
Seventy male ouibred Wistar/Cpb WU rais, weighing between 
200 and 300 g, were used They were housed with two ani-
mab per cage and had free access to water and standard labo-
ratory chow, which contained 21 7 IU reunol palmi tale per 
gram (diet AM II, Hope Farms, Woerden, the Netherlands) 
For the first experiment, in which anastomotic strength 
and hydroxyproline content were measured, the animals 
were randomly divided into five groups a control group 
(n= 11 ), a fluorouracil group (n-11), and three groups (n-10 
each) that received fluorouracil plus reunol, GM-CSF, or 
interleukin-2 All rats were killed 7 days after surgery 
The second experiment, measuring collagen synthesis, 
œnsistedofthreegroupsofanimals(n-6each) a control group, 
a fluorouracil group, and a group that received fluorouracil 
plus reunol These rats were killed 4 days after surgery 
The study was approved by the Animal Ethics Re-
view Committee of the Faculty of Medicine, University of 
Nijmegen (the Netherlands) 
DRUG ADMINISTRATION 
Fluorouracil was given intrapentoneally in a dosage of 20 
tng/kg of body weight This is the same dosage used be-
fore" and represents the highest dosage that, in combina-
tion with surgery, did not result in a significant mortality 
rate Fluorouracil was administered once a day, immedi-
ately after surgery and on the next 6 days, at a concentra-
tion of 1 mg/mL of saline solution 
Reunol pal mi taie was given orally (by gavage) from the day 
before surgery onward in a dosage of 5000 IU/kg per day 
Recombinant munne GM-CSF was dissolved in sodium 
phosphate. 20 mmol/L, pH 7 5, sodium chloride. 0 15 mol/L, 
and rat albumin, 5 mg/ml It was administered intrapen-
toneally immediately after surgery and on the next 3 days 
in a dosage of 5 μg (2 5 mL of the solution) per day Re­
combinant human interleukin-2 was reconstituted in wa­
ter and diluted with 5% wlAvt dextrose in water It was given 
subcutaneously (0 25 mL of solution) once a day from the 
day of surgery onward in a dosage of 2X 10й IU/kg of body 
weight 
In previous experiments that used the current model for 
intestinal healing, we established that anastomotic repair is 
not affected by daily administration of placebo solutions, ei­
ther by gavage or by intravenous, intraperitoneal, or subcu­
taneous injection (Τ H , unpublished data, 1990 and 1992) 
For this reason the animals in the present control groups re­
ceived intraperitoneal saline solution daily 
OPERATIVE PROCEDURE 
After an intraperitoneal injection of pentobarbital so­
dium, a midline incision was made, and 1 cm of both small 
and large bowel were resected at 15 cm proximal to the il­
eocecal junction and 3 cm proximal to the rectal perito­
neal reflection, respectively Continuity was restored mi-
crosurgically by the construction of an inverted one-layer 
seromuscular end-to-end anastomosis with eight inter­
rupted sutures of Θ-0 monofilament material (Ethicon, 
Somerville, Mass) The abdomen was closed in two layers 
with a continuous 3 0 silk suture for the fascia and with 
staples for the skin 
inhibit the growth of metastatic deposits and that its re­
moval can increase the growth rate of metastases 5 Experi­
mental data indicate that the efficiency of adjuvant therapy 
is inversely proportional to the time interval between sur­
gery and therapy Although, so far, limited information ex­
ists to support timing decisions in human neoplasms, the 
considerations mentioned above support the thesis that 
treatment with anticancer agents should begin at the day 
of surgery or as soon as possible thereafterJ ь 7 
Patients will present with recurrent disease at the op­
erative site or the pentoneal surface and/or with hepatic me­
tastases and systemic metastases Although percentages in 
the literature vary widely, local recurrence is high8 Ideally, 
an adjuvant surgical therapy should be effective at all sites 
ofreairTence.bothlocoregionalandsysternic However,elimi­
nation of recurrence at a particular anatomical site may ben­
efit a significant proportion of patients in terms of survival 
or quality of life Regional admimstrauon of cytostatic agents 
is expected to reduce systemic passage and thus general toxic 
effects, allowing higher local concentrations This fact is im­
portant in view of the fact that the fluorouracil response rate 
may depend strongly on dose intensity9 
A number of clinical studies using immediate (0 to 
4 days) postoperative intraperitoneal administration of 
fluorouracil are in progress,10 and a current European Or­
ganization for Research and Treatment of Cancer Trial 
(protocol 40911 ) has one arm in which patients are treated 
intrapentoneally with fluorouracil in the penoperative 
penod (Gastrointestinal Tract Cancer Cooperative Group, 
unpublished data, 1992) In an animal model of colon 
cancer, înirapentoneal administration of fluorouracil 
prevents pentoneal and hepatic metastasis " 
As interest in immediate postoperative local and/or sys-
temic adjuvant fluorouracil therapy rapidly increases, it be-
comes essential to delineate its hazards for anastomotic heal-
ing and to develop strategies to prevent negative effects 
because leakage of intestinal anastomoses is a potentially 
devastating surgical complication 
It was shown before that administration of fluoroura-
cil on the day of surgery and the next 2 days does not sig-
nificantly reduce strength in experimental intestinal anas-
tomoses l2 Recently, Graf etal11 reported that prolongation 
of the fluorouracil therapy impaired the healing of colonic 
anastomoses The present study desenbes the effects of a 
7-day course of intraperitoneal administration of fluoro-
uracil on repair of both ileal and colonic anastomoses in the 
rat In addition, we examine the potential beneficial effects 
of reunol palmi ta te, granulocyte macrophage colony-
stimulating factor (GM-CSF), and mterleukin-2 
Only one animal (from the fluorouracil/retinol group) died 
prematurely, owing to faulty oral admimstrauon of the drug 
All animals lost weight after surgery In all groups, av-
erage weight loss was 9% of body weight at the first day 
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ANALYTICAL PROCEDURES 
The rats were killed by an intraperitoneal overdose of pen­
tobarbital sodium After opening (he abdominal wound and 
identifying the anastomoses, the adhesions were cut as far as 
possible without injuring the intestine An intestinal segment 
with the anastomosis in the middle was removed, with the 
sutures left in place This segment was attached to an infu­
sion pump filled with methylene blue-stained saline solution 
The pressure was raised with an infusion rate of 4 mL/min and 
recorded graphically Both the bursting pressure (the maxi­
mum pressure recorded immediately before sudden loss of 
pressure) and the sue of rupture were noted Thereafter, the 
segment was placed in a lensiometer, and the breaking strength 
was recorded Thus, both the bursting pressure and the break­
ing strength were measured in the same anastomotic segment 
The validity of this procedure had been confirmed in a pilot 
experiment In two senes of animals, the breaking strength 
was measured directly or after the procedure to obtain the burst­
ing pressure Similar values for the average breaking strength 
were obtained in both senes (В M de Man and Τ H .unpub­
lished data, 1992} 
The anastomotic segment was then cleaned from the 
surrounding tissue, and a 5-mm segment with the suture 
line in the middle was collected The samples were frozen 
immediately and stored in liquid nitrogen until process­
ing After weighing, the samples were pulvenzed and ly-
ophilized, and the hydroxyprohne content was measured 
as described before и 
In the second expenment, collagen synthetic capac­
ity in control segments (removed at operation) and anas­
tomotic tissue were quantitaied by measunng the incor­
poration of proline into collagenase digestible protein (CDP) 
after surgery Thereafter, animals in the control group started 
to gain weight again, and at death, their average weight was 
6% over the weight at surgery Weight gain was retarded 
m the fluorouracil group (average weight at day 7 was 94% 
of weight at surgery, P= 0002 vs control group), whereas 
rats in the fluorouracil/GM-CSF and fluorouracil/ 
mterIeukm-2 groups lost progressively more weight, the 
average weight at day 7 being only 85% (P= 0007 vs fluo­
rouracil group) and ¿4% (P= 0006 vs Fluorouracil group), 
respectively, of the weight at surgery In the group that re-
ceived retinol in addition to fluorouracil, average weight 
at day 7 was 98% of the initial weight (P= 0004 and P= 08 
vs control and fluorouracil group, respectively) 
Average anastomotic breaking strength is depicted 
in Figure 1 Administration of fluorouracil resulted in sig-
nificantly reduced a nas to mo uc strength breaking strength 
was lowered by 41% in ileal anastomoses and by 44% in 
the colonic anastomoses Addition of GM-CSF or inter-
leukm-2 did not improve anastomotic strength If the ani-
mals were given retinol and fluorouracil, the resulting 
breaking strength was significantly higher than that in 
rats receiving fluorouracil only Although mean values 
were still lower than those of the control group, the dif-
ference was not statistically significant 
Η μ ι · 3 shows the values for the bursting pres­
sure obtained from the individual animals In some ani­
mals, notably those from the fluorouracil/interleukin-2 
group, it proved to be technically difficult to prepare the 
ARCH 
according to a procedure validated before for rat intestinal 
tissue " " Briefly, freshly collected tissue expiants of I to 2 
mm
1
 were incubated in a medium containing tnliated pro­
line for 3 hours, and the radioactivity incorporated into total 
protein was measured Subsequently, to determine proline in 
corporation into collagen, excess purified collagenase was 
added The radioactivity in the supernatant represents CDP 
as a measure of the amount of collagen synthesized Subtrac­
tion of the radioactivity in the CDP fraction from that in 
total protein yields the incorporation into noncollagenous 
protein (NCP) The relative collagen synthesis (RCS) was cal­
culated with a formula17 that lakes into account the enrich­
ment of proline in collagen compared with other proteins 
Percentage of RCS-(CDP/I(NCPX5 4)+CDP])X100% 
Incorporation is expressed on the basis of sample wet weight, 
DNA18 content, or protein" content 
STATISTICAL ANALYSIS 
The main questions to be answered were the following are 
anastomotic strength and hydroxyprohne levels reduced 
in the four groups receiving fluorouracil when compared 
with the control group, and second, are these variables im­
proved in the fluorouracil/retinol, fluorouracil/GM-CSF, and 
fluorouracil/inierleukin-2 groups when compared with the 
fluorouracil group? To correct for the faci that multiple com­
parisons were made, pairwise comparisons were done us­
ing a level of significance of a'» 2a/k, where к is the total 
number of pairwise comparisons Thus, differences be­
tween groups ( И д т · 1 and Hpiw 3) were considered 
significant (n= 05) at P<a', where a'» 014 The lesi used 
was a one-tailed Wilcoxon test 
F)|ura 1 Anastomotic breaking strength Bars represent mean*SD values 
Asterisk denotes significantly (P<a where a ' - 014 [see "Methods" 
section]) different trom contro) group dagger significantly different from 
fluorouracil group and double dagger, nearly significantly (α'<Ρ<2α') 
different from fluorouracil group 
anastomotic segment for this analysis As a consequence 
of iatrogenic damage, no bursting pressure could be mea­
sured in three ileal and two colonic anastomoses from this 
group and in one ileal anastomosis from the fluorouracil 
group In the control group, the bursting site was always 
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Figure 2 Anastomotic hydroxyproline concentration and content Bars 
represent mean+SD values Asterisk denotes significantly (P<a where 
a = 014 [see 'Methods' section)) différent from control group dagger 
significantly different from fluorouracil group and double asterisks nearly 
significantly (a <P<2a ) different Horn control group 
outside the suture line, meaning that the actual value no 
longer reflects wound strength because the anastomoses 
had grown stronger than the adjacent tissue This was not 
the case in the other groups In the fluorouracil group, rup-
ture occurred within the anastomotic area in nine of 21 
cases, confirming the reduction of anastomotic strength 
also observed by measunng the breaking strength A simi-
lar phenomenon was observed in the groups that re-
ceived additional GM-CSF or interleukin 2 Again, addi-
tion of retmol appeared to improve strength in this group, 
only four of IB wounds ruptured within the suture line 
This eiïect is also apparent if the mean anastomotic burst-
ing pressures were calculated using only those cases in 
which rupture occurred within the anastomosis For in-
stance, for ileum, these mcan±SD values were 94±38 
mm Hg (n=5) in the fluorouracil group and 190±4O (n=3), 
93±52 (n=6), and 123+44 (n=5) mm Hg in the iluoro-
uracil/retinol, fluorouracil/GM-CSF, and fluorouracil/ 
mterleukin-2 groups, respectively 
Tissue hydroxyprohne levels were quantified as a mea-
sure of collagen levels, and the average values for hydroxy-
proline concentration and content in a 5-mm anasto-
motic segment are shown in Tigure 2 In the fluorouracil 
group, anastomotic hydroxyprohne concentration and con-
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uninjured intestine collected at surgery in animals from the control group 
Values are calculated if synthesis is quantrtated on the basis of wet weight 
DNA content or protein content or as relative collagen synthesis 
tent were lower than in the control group The same was 
true for the fluorouracil/GM-CSF group and the fluorouracil/ 
interleukin-2 group Addition of retino! appeared to pre­
vent the decrease in hydroxyprohne concentration and to 
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a l efficacy through biochemical modulation However, cur­
rent efforts to improve outcome are also directed al opti­
mizing fluorouractl treatment schedules with respect to 
dosage and liming and route of administration 
In relation to the aspect of timing, interest in im­
mediate postoperative fluorouracil therapy is growing 
In an effort to reduce the incidence of hepatic metasta­
sis, several recent trials have explored the efficacy of pen-
operative portal vein infusion of fluorouracil7 Also, a num­
ber of clinical studies using perioperative intraperitoneal 
administration of fluorouracil are in train (Ghmcliusand 
Pâhlman10 and the Gastrointestinal Tract Cancer Coop-
erative Group, unpublished data, 1992) Thus, research 
into the effects of perioperative fluorouracil on the heal-
ing of intestinal anastomoses is highly indicated 
It is to be expected that the occurrence of any nega-
tive effect of fluorouracil administration on anasto-
motic healing will depend on the time of administration 
with respect to surgery Probably, postponement of 
therapy until after the cellular phase of healing, when the 
wound has gained sufficient strength, will prevent any 
danger for anastomotic insufficiency If treatment is started 
immediately after surgery, the chances for complica-
tions may increase Still, Hillan et al21 concluded that early 
postoperative intraperitoneal administration (at 0 to 4, 
3 to 7, or 7 to 12 days after surgery) of fluorouracil does 
not impair the healing of experimental colonic anasto-
moses However, a major drawback of their study is the 
fact that anastomotic strength was assessed only after 14 
days, whereas eventual detrimental effects in the Tirsi week 
when strength is still low under normal healing condi-
tions are of more potential significance It was found that 
three intraperitoneal doses of fluorouracil (at 0 to 2 days 
after surgery) slightly but not significantly lowered anas-
tomotic breaking strength and collagen content of 3- or 
7-day-old intestinal anastomoses n Our data show that 
continuation of treatment may result in a severe reduc-
tion of both anastomotic bursting pressure and break-
ing strength at 7 days after surgery This outcome agrees 
with the recent findings of Graf et al,,3 who reported re 
duced breaking strength of colonic anastomoses after a 
similar fluorouracil regimen 
Assuming that wound strength is ultimately de-
cided by collagen (either its quantity or its quality). 
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tSignificantly different from control group (Wikoxon two sample test) 
limit the lowenng of hydroxyprolme content, induced in 
ileal anastomoses by fluorouracil 
We also compared the collagen synthetic capacity, 
measured ex vivo in tissue expiants, in the control fluo-
rouracil, and fluorouracil/retinol groups Anastomouc col-
lagen synthetic capacity was increased greatly 4 days af-
ter surgery Vlgvr· 4 shows that, in the control group, 
absolute collagen synthesis was enhanced approxi-
mately 10-fold in ileal anastomoses and fourfold in co-
lonic anastomoses Although synthesis of NCP was also 
stimulated (data not shown), the increase was relatively 
specific for collagen, as indicated by the considerable en-
hancement of the percentage of RCS 
The average anastomotic synthetic capacity in ileum 
and colon of the various groups is given ш ТаЫ· 1 and 
ТаЫ« %, respectively Clearly, administration of fluoro­
uracil resulted in a specific and significant reduction of col­
lagen production capacity This effect was seen irrespec­
tive of whether synthesis was expressed on the basis ofwel 
weight, DNA content, or protein content The capacity to 
produce NCP was hardly affected Administration of reti-
nol together with fluorouracil did not change the synthe­
sis in ileal anastomoses compared with administration of 
fluorouracil alone In contrast, retinol appeared to stimu­
late collagen synthetic capacity in the colonic anastomo­
ses IfcollagensynthesiswasexpressedonthebasisofDNA 
or protein content or as RCS, values in the fluorouracil/ 
retinol group were significantly higher than in the fluoro­
uracil group and no longer significantly different from those 
observed in the control group In addition, the produc-
Uon capacity for NCP appeared to be significantly lower 
in the fluorouracil/retinol group than in the control group 
Trials for adjuvant chemotherapy for colorectal cancer be 
gan in the 1950s Until now, disappointing results have been 
obtained despite enormous preclinical and clinical re­
search efforts For more than 30 years, fluorouracil has been 
the mainstay of therapy, and today it remains the most ef­
fective single agent in the treatment of this disease, al­
though a meta-analysis of phase 111 randomized control Di­
als showed only limited benefit to its use M Much attennon 
is directed at examining methods of enhancing fluoroura-
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changes in collagen metabolism are expected to affect 
anastomotic strength The capacity for anastomotic col­
lagen synthesis in the fluorouracil group was only half 
that in the control group This may explain the reduced 
anastomotic hydro xyp rol ine content, although we can­
not yet preclude the possibility of concomitant in­
creased degradation of existing collagen fibers It thus 
seems likely that a diminished presence of collagen con 
tributes to loss of strength, as observed in the fluoro­
uracil group, although changes in its quality, eg, the de­
gree of cross-linking, may also play a role 
Wound collagen synthesis is primarily a task for the 
fibroblast Suppressed synthesis by fluorouracil adminis­
tration may be due to a direct toxic effect on fibroblasts or 
to suppression of regulatory inflammatory cells like Τ lym­
phocytes and macrophages The latter play a central role 
in the repair sequence " " Chemotherapy is known to de­
crease the number of monocytes In earlier experiments, 
indications that a penoperative regimen of cytostatic drugs, 
including fluorouracil, delays the appearance of macro­
phages in the anastomotic area were found u Because re­
combinant munne GM CSF has been reported to induce 
monocytosis and to increase the number of tissue macro-
phages,"·2" и seemed worthwhile to investigate whether ad­
ministration of this compound could ameliorate fluoro-
uracil-impaired healing However, when given for 4 
consecutive days from the day of surgery onward in a dose 
that had been proven effective in eliciting the desired he-
mapoietic response in rodents,25 lb it did not improve heal­
ing The animals in the fluorouracil/GM-CSF group lost pro­
gressively more weight than did those in the fluorouracil 
group, and anastomotic repair was not stimulated If any­
thing, anastomotic bursting pressure and hydroxyproline 
levels were reduced even further 
Major surgery impairs the cellular immune 
response It has been suggested that fluorouracil-based 
chemotherapy is associated with suppression of immune 
function 2T Thus, penoperative fluorouracil therapy might 
result in depressed function of macrophages and Τ lym­
phocytes Stimulation of these cells might improve fluo-
rouracil-suppressed healing Interleukin-2, which 
supports the growth and function of activated Τ cells and 
macrophages, has been reported to improve cutaneous heal­
ing in rats treated with doxorubicin hydrochloride (Adna-
mycin) M Interleukin-2 reverses the deletenous effects, sup­
posedly caused by immunosuppression, of blood transfusion 
on anastomotic healing w Penoperative immunotherapy 
with interleukin-2 has been suggested as a means to im 
prove the cellular immune system of patients undergoing 
surgery for colorectal cancer w Still, daily administration 
of interleukin-2 to the fluorouracil-treated rats in a dose 
that effectively stimulated transfusion-suppressed healing 
did not improve anastomotic healing wound strength and 
collagen content were similar in the fluorouracil and fluo-
rouracil/inlerleukin-2 groups 
Retinol is one of the retinoids that have a profound im­
pact on many biological functions The apparent antitumor 
effects of retinoids have generated renewed enthusiasm for 
their application in clinical studies for oncologic therapeu­
tic indications il The healing promoting capacity of reti-
nol, especially under conditions that retard repair, has been 
reported repeatedly It has been shown to improve vanous 
aspects of healing in experimental cutaneous wounds in 
which repair was suppressed by steroids," induced diabe­
tes," irradiation * or tumor implantation "With regard to 
anastomotic healing, Winsey et al te found that retino! supple­
mentation mitigated the negative effects of preoperative ir­
radiation on the bursting pressure and hydroxyproline con­
centration in 7-day-old rat colonic anastomoses Interpre­
tation of their data is hampered because no data on bursting 
sue were supplied The same is true for a recent report that 
showed that high-dose retinol therapy reversed the inhibi­
tory effects of long-term administration of corticosteroids 
on the healing of ileal and colonic anastomoses " 
Our findings indicate that admimstrauon of reunol may 
be useful in preventing the loss of early anastomotic strength 
that is induced by the use of cytostatic drugs administered 
from the day of surgery onward Although atl animals did 
receive retinol in their standard diet (up to an estimated 
800 lU/kg per day), administration of additional retinol en­
hanced anastomotic breaking strength in animals receiv­
ing fluorouracil It also improved the bursting pressure, re­
ducing the frequency of bursting that occurred within the 
suture line In those anastomotic segments m which the 
bursting site was within the anastomosis, the actual burst­
ing pressures measured were higher in the fluorouracil/ 
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retinol group than in the Fluorouracil group It is conceiv­
able that augmentation of the retino! dose may further 
enhance its efficacy The dose given, 5000 IU/kg per day, 
is well below those administered to reverse the negative ef­
fects of corticosteroids on wound repair " w 
The mechanism by which retinol antagonizes the ef­
fect of Iluorouracil remains to be elucidated Retinol admin­
istration may enhance the early inflammatory reaction to 
wounding, increasing the number of monocytes and mac­
rophages at the injury site w Speculation also exists regard­
ing stimulation of collagen synthesis and inhibition of col­
lagen degradation (Weinzweig et al3' and Phillips et al") 
We have found no consistent support for a stimulation of 
collagen synthesis In ileal anastomoses, the collagen syn­
thetic capacity was similar in the Fluorouracil and Fluorouracil/ 
retinol groups, whereas the average anastomotic hydroxy-
proline content appeared to be increased in the Iluorouracil/ 
retinol group (and not significantly lower than in the control 
group) lntliecolon.thecoUagensyntheuccapacitywashigher 
in the fluorouracil/retmol group than m the fluorouracil group 
whereas the hydroxyprohne content was similar in both 
groups It should be emphasized that the hydroxyprohne 
content was measured in a 5 mm segment containing un­
injured tissue next to the suture line Thus small and local 
changes in either collagen degradation or collagen synthe­
sis may remain undetected Whatever mechanism is respon­
sible for the gain in wound strength, the beneficial effects 
observed in the present study seem to be of potential clini­
cal interest and warrant further investigation 
In summary, daily intraperitoneal administration of 
fluorouracil from the day of surgery onward considerably 
reduced anastomotic strength after 7 days This may have 
been caused by a reduction in collagen synthetic capac­
ity within the wound area Loss of strength could not be 
prevented by additional administration of GM CSF or 
interleukin-2, but the negative effects of fluorouracil were 
ameliorated by oral administration of retinol 
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Introduction 
Surgery remains the only potentially curative treatment modality for early-stage colorectal 
cancer, but a majority of the patients presenting with this disease are candidates for 
adjuvant chemotherapy because of their limited chances for 5-year survival [1]. Massive 
preclinical and clinical research efforts have shown that 5-fluorouracil is the most effective 
single agent to be used as an adjunct to surgery for colorectal cancer and current 
research aims to improve its efficacy by combinations with other agents [2,3]. In this 
respect, its combination with levamisole has yielded promising results [4]. Although major 
questions still have to be resolved concerning timing and route of administration of 
cytostatic agents, there exists growing interest in the use of immediate post-operative 
adjuvant therapy after resection of intestinal malignancies [5-7]. 
It thus becomes necessary to investigate the potential effects of such therapies on the 
healing of intestinal anastomoses. In previous experimental studies in the rat we have 
shown that peri-operative administration of 5-fluorouracil may severely impair the 
development of anastomotic strength [8]. This loss of strength is accompanied by a 
reduced collagen synthetic capacity and lowered accumulation of collagen in the wound 
area. Levamisole, alone or in combination with 5-fluorouracil, also appears to compromise 
intestinal repair [9]. 
The proliferation phase of the wound healing sequence is dominated by the fibroblasts. 
These cells are the primary source for collagen, on which protein wound strength 
essentially depends. In fact, the number of fibroblasts participating in repair is often an 
indirect measure of the development of wound strength [10]. Anastomotic repair in the 
intestine is characterized by a massive increase in collagen synthesis during the early 
post-operative period [11,12]. The current study describes the direct effects of 5-
fluorouracil and levamisole, alone and in combination, on fibroblast proliferation and 
collagen synthesis measured in vitro. In addition, we have collected serum from rats, 
which had been treated with these drugs, and investigated if it would impede these cellular 
functions. 
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Materials and Methods 
Materials 
All supplies for cell culture were purchased from Life Technologies (Breda, The 
Netherlands). 5-Fluorouracil was obtained from Abie (Netanya, Israel) and levamisole from 
Janssen (Beerse, Belgium). L-[2,3-3H]proline (1.41 TBq/mmol) and [6-3H]thymidine (999 
GBq/mmol) were purchased from Amersham International, Little Chalfont, England. 
Collagenase (type VII) was obtained from Sigma (St. Louis, U.S.A.). All other reagents 
were of analytical grade (Merck, Darmstadt, Germany). 
Animals 
In order to obtain normal rat serum (NRS) for maintaining the rat fibroblast cultures, a 
serum pool was formed from blood collected from young adult male Wistar rats. 
Post-operative rat serum was obtained from animals used for parallel studies on intestinal 
anastomotic healing [9]. Rats underwent resection and anastomosis of both the small and 
large bowel and groups of animals received intraperitoneal 5-fluorouracil (20 mg/kg body 
weight), oral levamisole (5 mg/kg body weight) or both immediately after operation and on 
the next two days. A control group received saline only. Three days after operation all 
animals were killed and serum was collected and stored at -80°C. 
The experiments were approved by the Animal Ethics Committee of the Medical Faculty of 
the University of Nijmegen. 
Cell culture 
Rat skin fibroblast lines were obtained from expiants of skin biopsies from young adult 
male Wistar rats. They were grown in Roswell Park Memorial Institute medium 
(RPMI1640, Dutch modification) supplemented with 2 mM L-glutamine, 1 mM Na-
pyruvate, antibiotics (40 μg/ml gentamycin) and 10% heat-inactivated fetal calf serum 
(FCS) at 37*C in a 5% C02, 95% air humidified atmosphere. Cells were used before the 
10th passage. Cell counting was performed on a Coulter Counter ZM (Coulter Electronics, 
Mijdrecht, The Netherlands). 
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Assay of fibroblast proliferation 
Freshly trypsinised fibroblasts were plated in 96-well microtitre plates (6 wells for each 
experimental condition) at a density of approximately 2 χ 103 cells/well in 0.1 ml RPMI plus 
10% FCS. After a 4 h incubation the medium was replaced by 0.1 ml RPMI and the cells 
were incubated for another 18 h. Subsequently, the medium was replaced again by 0.1 ml 
RPMI plus 1% NRS and incubation continued for another 48 h. In various experiments this 
medium was supplemented with 5-fluorouracil or levamisole (or both) or the concentration 
or composition of the rat serum was varied. Thereafter, 18.5 KBq [3H]thymidine (in 10 μΙ 
RPMI) was added and incubation continued for a final 24 h, followed by removal of the 
medium, trypsinisation and harvesting of the cells (on a LKB Wallag cell harvester) and 
counting of the thymidine incorporation. 
Assay of fibroblast collagen production 
Assay of collagen production by steady state, visually confluent fibroblasts was assessed 
over a 24-h period by [3H]proline incorporation into collagenous protein. 
Freshly trypsinized fibroblasts were plated in 24 wells plates at a density of approximately 
3x104 cells/well in 1 ml RPMI plus 10% FCS. Three days after plating the medium was 
removed from the confluent cells and replaced, after washing the cells twice with 
phosphate buffered saline, by 0.4 ml RPMI plus ascorbic acid (50 мд/ті) with 1% NRS. In 
various experiments this medium was supplemented with 5-fluorouracil or levamisole (or 
both) or the concentration or composition of the rat serum was varied. Twenty four hours 
later the medium was replace by 0.4 ml of the same medium plus B-aminopropionitrile (50 
pg/ml) and 74 KBq/ml [2,3-3H]proline for the final 24 h of culture. 
After the labeling period 0.2 ml of 50 mM Tris-HCI pH 7.6 containing 0.25 M 
ethylenediaminetetraacetic acid (EDTA), 0.1 M N-ethylmaleimide (NEM) and 10 mM 
phenylmethylsulfonylfluoride (PMSF) was added to each well and the total content was 
removed. The wells were washed twice with 1 ml 50 mM Tris-HCI pH 7.6 containing 1 mM 
proline. The wash solutions were combined with the suspension containing cells and 
medium and 0.2 ml bovine serum albumin (4.25% w/v) was added. The final suspension 
was freeze/thawed 3 times and the proteins were precipitated with trichloroacetic acid 
(TCA; final concentration 10%). The radioactive protein was separated from free 
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[3H]proline by repeated (3x) washes with 5% TCA containing 1 mM proline at 4°C. 
The final sediment was dissolved in 0.75 ml 0.2 M NaOH and neutralized by the addition 
of 0.3 ml 1 M HEPES and 0.3 ml 0.15 M HCl. Aliquote from this solution (0.1 ml) were 
counted to determine the incorporation in total protein. In order to quantitate proline 
incorporation into collagen 0.2 ml 20 mM Tris-HCI pH 7.6 containing 50 mM CaCI2 and 0.1 
ml (27 IU) collagenase were added to a 0.5 ml aliquot of the solubilized sample and the 
mixture was incubated for 3 h at 37°C. The digestion was terminated by the addition of 
TCA and tannic acid up to final concentrations of 0.3 M and 1.5 mM, respectively. After 
centrifugation (10 min Ю.ОООхд) a 1 ml aliquot of the supernatant was counted in a liquid 
scintillation analyzer. The same procedure was followed without the addition of 
collagenase. Subtraction of the counts released during this control incubation from those 
released in the presence of collagenase yielded the collagen-specific incorporation, which 
will be referred to as collagenase-digestible protein (CDP). Subtraction of the radioactivity 
in the CDP fraction from that in total protein yields the incorporation into non-collagenous 
protein (NCP). Incorporation into CDP and NCP is quantified per well. 
The relative collagen synthesis was calculated with the formula [13] that takes into 
account the enrichment of proline in collagen compared to other proteins: 
CDP 
RCS = % Relative Collagen Synthesis = χ 100%. 
(NCP χ 5.4) + CDP 
For each experimental condition, six wells were used: four wells for the actual 
measurement of [3H]proline incorporation and two wells for a cell count at the completion 
of the incubation period. 
Statistical analysis 
Differences between control and drug-treated cultures were tested for significance 
(p<0.05) using a two-sided Student t-test. 
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Results 
Addition of 5-fluorouracil to the culture medium resulted in a marked, dose-dependent 
suppression of DNA synthesis in actively dividing cultures of rat skin fibroblasts in the 
logarithmic growth phase (Figure 1). Inhibition was significant from concentrations of 1 μΜ 
upwards and a 50% inhibition was observed at a concentration of approximately 20 μΜ. 
Percent of control 
100 
50 
control -7 -6 -5 -4 -3 
Log 5-FU concentration (M) 
Figure 1: Effect of 5-fluorouracil on fibroblast proliferation. The average (+ SD) of six measurements is given as 
percentage of [3H]thymidme incorporation in the absence of 5-fluorouracil. *: ρ < 0.05 vs control. 
Figure 2 (upper panel) shows that levamisole also suppressed fibroblast proliferation, but 
from a concentration of 10 μΜ upwards: a 50% inhibition was found at a concentration of 
approximately 0.1 mM. However, if levamisole was added together with a low (0.1 μΜ) 
concentration of 5-fluorouracil, which in itself did not decrease thymidine incorporation, its 
anti-proliferative effects became apparent at concentrations as low as 1 μΜ (Figure 2, 
middle panel). The same phenomenon was observed if levamisole was added together 
with 10 μΜ 5-fluorouracil (Figure 2, lower panel). Apparently, a small dose of levamisole 
was able to strongly potentiate 5-fluorouracil induced suppression of fibroblast 
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proliferation. 
3ercent of control 
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control -6 -5 -4 -3 
Log levamisole concentration (M) 
Figure 2: Effect of levamisole on fibroblast proliferation. Results are given for the effect of levamisole alone (upper 
panel) or in the presence of 0.1 μΜ (middle panel) or 10 jtM (lower panel) 5-fluorouracil. The average (+ SD) of six 
measurements is given as percentage of [^thymidine incorporation in the absence of 5-fluorouracil. *: ρ <0.05 vs 
control. 
The experiments on collagen synthesis were performed with cultures of confluent, non-
dividing fibroblasts. Under these conditions, the addition of neither 5-fluorouracil nor 
levamisole (nor their combination) did significantly affect the number of viable cells 
present. The effect of 5-fluorouracil on fibroblast collagen synthesis is depicted in Figure 
3. If 5-fluorouracil was added only during the final 24 h of incubation, collagen synthesis 
was inhibited by 20% in the 1-10 μΜ range; this effect did not persist at higher 
concentrations. However, if 5-fluorouracil was present over an 48 h period, all 
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However, if 5-fluorouracil was present over an 48 h period, all concentrations from 1 μΜ 
upwards significantly reduced the production of collagenase-digestible protein per cell. 
This effect was not specific for collagen since the percentage relative collagen synthesis 
remained unaltered. 
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Log 5-FU concentration (M) 
Figure 3: Effect of 5-fluorouracil on fibroblast collagen synthesis. Results are the average (+SD) of four cultures. 
The upper panel represent the absolute collagen synthesis, calculated as radioactivity incorporated in collagenase-
digestible protein (CDP), the lower panel the relative collagen synthesis (RCS) calculated as a percentage of total 
protein synthesis. Grey bar represent controls black bars results after 24 h incubation with 5-fluorouracil and open 
bars results after 48 h incubation with 5-fluorouracil. *: ρ < 0.05 vs control. 
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Log levamisole concentration (M) Figure 4: Effect of levamisole on fibroblast collagen synthesis Results are given for the effect of levamisole alone 
(upper panel) or in the presence of 0 1 μΜ (middle panel) or 10 μΜ (lower panel) 5 fluorouracil The average ( + 
SD) of four measurements is given for the absolute collagen synthesis calculated as radioactivity incorporated in 
collagenase-digestible protein CDP) * ρ < 0 05 vs control 
Collagen synthesis in the presence of increasing concentrations of levamisole is shown in 
Figure 4 (upper panel) Neither collagen production nor the production of non-collagenous 
protein (not shown) was affected by levamisole in concentrations up to the mM range If 
levamisole was added in the presence of 0 1 μΜ 5-fluorouracil, which concentration did 
not effect synthesis, the highest levimasole concentration tested seemed to have an 
inhibitory effect at 1 mM the collagen synthesis was slightly, but significantly, reduced 
(Figure 4, middle panel) This potentiating effect of levamisole was also found if the drug 
was added in the presence of 10 μΜ 5-fluorouracil This concentration of 5-fluorouracil 
reduced synthesis by 50% Addition of 1 mM levamisole resulted in a further 30% 
inhibition of fibroblast collagen synthesis (Figure 4, lower panel) The reduction appeared 
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to be specific for collagen since the relative collagen synthesis decreased from 6.5 ± 0.4 
to 4.8 ± 1 . 2 % . 
In order to investigate if the post-operative administration of 5-fluorouracil and/or 
levamisole induced the sustained presence of circulating compounds which would 
interfere with fibroblast functions, we examined the effects of increasing concentrations of 
rat serum on fibroblast proliferation and collagen synthesis. Figure 5 compares the effects 
of serum obtained from control (operated) rats with serum from rats which had received 5-
fluorouracil. The serum from both groups of rats equally affected fibroblast proliferation 
and collagen synthesis. Serum collected from rats which had received either levamisole or 
5-fluorouracil plus levamisole [9] showed similar effects (results not shown). 
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Figure 5: Effect of serum concentration on fibroblast collagen synthesis and proliferation. Upper panel: average 
(+SD) of four wells for measurement of absolute collagen synthesis. Lower panel: average (+SD) of six wells for 
measurement of proliferation. Black bars: pooled serum from operated (cf. methods) rats; open bars: pooled serum 
from operated rats treated with 5-fluorouracil. 
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Discussion 
5-Fluorouracil and levamisole, if administered alone or together in the immediate post­
operative period, may impair the development of strength in experimental intestinal 
anastomoses and thus increase the chances for anastomotic dehiscence [9]. Elucidation 
of the mechanisms involved is necessary in order to find ways to avoid this unwanted 
phenomenon. The present results indicate that direct inhibition of essential fibroblast 
functions may be responsible for the negative effects of these drugs on wound repair. 
Fibroblasts are essential to the repair sequence, especially in terms of the deposition of 
the new extracellular matrix [14]. Thus, fibroblast migration, proliferation and production of 
matrix components are fundamental to adequate healing. 
It is to be expected that an anti-proliferative agent like 5-fluorouracil will inhibit proliferation 
in actively dividing cell cultures. Still, in earlier studies we found the proliferation of human 
skin fibroblasts to be refractory to 5-fluorouracil concentrations up to 50 μΜ [15]. In these 
experiments the drug had only been present for 24 h. The present results, obtained after 
an 72 h incubation with 5-fluorouracil, show a 50% inhibition of proliferation at a 
concentration of approximately 20 μΜ. Apparently, the inhibition of proliferative activity 
strongly depends on the time of exposure, which phenomenon has also been reported for 
ocular (subconjunctival) fibroblasts [16]. 
Very little has been reported on the possible effects of 5-fluorouracil on matrix production. 
In our previous study mentioned above [15], non-dividing cultures of human skin 
fibroblasts were exposed for 24 h to 5-fluorouracil concentrations up to 50 μΜ without 
affecting basal collagen synthesis, while transforming growth factor-ß-induced collagen 
synthesis was inhibited at - pharmacologically relevant - drug concentrations between 1 
and 10 μΜ. However, like proliferation, suppression of collagen synthesis appears 
dependent on time of exposure: incubation of fibroblasts for 48 h with 5-fluorouracil in 
concentrations of 1 μΜ and higher results in a consistent reduction in the amount of 
collagenase-digestible protein per cell. Since these results were observed in confluent, 
non-dividing cell cultures, it seems likely that the inhibitory effect is the result of a RNA-
directed, rather than a DNA-directed action of 5-fluorouracil [17]. 
5-Fluorouracil, administered daily as an intraperitoneal bolus of 20 mg/kg body weight 
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from the day of operation onwards, strongly suppresses the healing of intestinal 
anastomoses in the rat [8,9,18]. Such drug regimen does not appear to lead to a 
sustained presence of circulating compounds which affect fibroblast functions most 
relevant to repair. While both fibroblast collagen synthesis and proliferation, as measured 
in vitro, depend on the presence of serum, we found no indications that these processes 
are compromised by serum collected from the 5-fluorouracil-treated animals. This may not 
be surprising since 5-fluorouracil which is not taken up by cells is inactivated and 
eliminated rapidly [19]. Still, although we do not know which concentrations of 5-
fluorouracil are actually achieved in the wound area, the current data suggest it to be very 
well possible that the drug effects detrimental to repair are caused solely by direct 
inhibition of fibroblast proliferation and collagen synthesis. 
The use of levamisole, together with 5-fluorouracil, is recommended for node-positive 
patients with colon cancer [20]. It has been proposed that the favorable effects of 
levamisole are due to the enhancement of the body's immune response rather than the 
biochemical modulation of 5-fluorouracil [21,22]. However, the mechanisms of interaction 
between these two agents largely remain to be elucidated, as has the optimal sequence 
and schedule of this drug combination. Previous research has established that levamisole, 
given alone or simultaneously with 5-fluorouracil, may be detrimental to wound repair [9]. 
The present results indicate that levamisole in itself can inhibit fibroblast proliferation. A 
significant reduction is achieved at a concentration of 0.1 mM which is much higher than 
those achieved clinically [22]. However, if levamisole is combined with a dose of 5-
fluorouracil, which is so low as not to affect fibroblast proliferation, addition of only 1 μΜ 
levamisole reduces proliferation by 70%. Thus, in this respect levamisole, at a 
pharmacologically relevant concentration, appears indeed to potentiate 5-fluorouracil 
toxicity. It is notewhorthy that levamisole, up to concentrations of 3 μΜ, reportedly has no 
demonstrable effects on 5-fluorouracil cytotoxicity in human colon cancer cells in vitro [23]. 
It has been reported that 2 mM levamisole strongly inhibits the production of type X 
collagen, though not that of type II collagen, in chick chondrocytes by reducing the gene 
transcription rate [24]. However, our data show that levamisole, in concentrations up to 1 
mM, does not appear to affect collagen synthesis in skin fibroblasts. Interestingly, the 
combination of 1 mM levamisole with either 0.1 or 10 μΜ 5-fluorouracil results in a limited, 
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but significant, lowering of fibroblast collagen production. Although this concentration 
presumably far surpasses the clinically relevant range, it remains noticable that in this 
respects levamisole is also able to potentiate the effect of 5-fluorouracil. 
Altogether, our data suggest that the impairment of wound healing by (combinations of) 5-
fluorouracil and levamisole, as observed by us before in animal studies, may largely be 
explained by direct effects on fibroblast function. While its mechanism remains to be 
elucidated, a synergystic effect between 5-fluorouracil and levamisole with regard to both 
proliferative and synthetic functions of the fibroblast has been demonstrated. Thus, in the 
context of wound repair, concurrent administration of these two drugs in the immediate 
post-operative period may, next to improving cytotoxicity for tumor cells, certainly be 
harmfull for essential reparative functions of other cells. 
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SUMMARY 
Although surgery remains the only curative treatment modality for colorectal cancer, 5-
years survival is still disappointingly low. Adjuvant chemotherapy may improve the 
outcome, especially in node positive patients. Untili now, 5-Fluorouracil (5-FU) has been 
the mainstay of chemotherapy for colorectal cancer. Massive efforts, both preclinical and 
clinal, are directed at finding ways to improve its efficiency, for instance by biochemical 
modulation of its activity. In addition, the dose, timing and route of administration of 5-FU 
remain a topic of debate, but there are excellent reasons to start the chemotherapy 
immediately after operation. As a consequence, the interest for immediate postoperative 
adjuvant 5-FU therapy increases rapidly. It therefore becomes imperative to asses the 
potential effects of 5-FU on the healing of intestinal anastomoses. 
This thesis describes the effects of perioperative 5-FU on the healing of anastomoses in 
both ileum and colon and explores ways to prevent its negative influence. In addition, 
experiments are reported which aim to investigate to what extent drugs like leucovorin, 
levamisole and interferon-α - which are thought to enhance 5-FU anti-tumor activity - add 
to the negative effects of 5-FU on anastomotic repair. 
For this purpose we have used an experimental model in the rat to study the first week of 
healing, where wound strength is relatively low and loss of strength may lead to 
anastomotic dehiscence. Parameters for repair were anastomotic strength, anastomotic 
collagen content and the anastomotic collagen synthetic capacity. 
Chapter 1 consists of a review of the relevant literature. Incidence, pathology and surgical 
treatment of colorectal cancer are discussed briefly, followed by a short review of adjuvant 
chemotherapy. Since 5-FU remains the cornerstone of adjuvant therapy, attention is paid 
to its metabolism and the potential benefits of biochemical modulation of its activity. The 
general mechanisms in wound healing are described and the importance of collagen 
metabolism for restoration of wound strength is emphasized. The final part focusses on 
wound repair in the intestine and the parameters to study this process in experimental 
models. 
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In chapter 2 we describe the effects of a short course (3 days) of immediate postoperative 
5-FU on the healing of intestinal anastomoses in the rat. We examined the potential 
difference between intravenous and intraperitoneal administration since the effect of local 
application of 5-FU could easily differ from that induced by systemic administration. Three 
groups of rats (n=20 each, one control group and two experimental groups) underwent 
resection and anastomosis of both ileum and colon and 5-FU (20 mg/kg body weight) was 
given, either intravenously or intraperitoneally, on the day of surgery and the two subse-
quent days. Healing was assessed three and seven days after operation. 
Administration of 5-FU led to a reduced white blood cell count. However, anastomotic 
strength was not significantly reduced at either time point and anastomotic hydroxyproline 
content (as a measure of collagen content) was not significantly affected. There were no 
differences in intestinal healing between intravenously or intraperitoneally administered 5-
FU. These results suggest that limited use of 5-FU during or immediately after operation 
does not necessarily affect early anastomotic healing in the intestine. 
Chapter 3 describes a study which was undertaken to assess if medication with 
leucovorin or levamisole, together with 5-FU, would result in negative effects on 
anastomotic repair. Five groups (n=20) of rats underwent resection and anastomosis of 
both ileum and colon: a control group and four experimental groups receiving 
intraperitoneal 5-FU, 5-FU plus leucovorin (10 mg/ kg body weight intravenously), 5-FU 
plus levamisole (5 mg/kg body weight orally) or levamisole alone, respectively, on the day 
of surgery and the next two days. Animals were killed three or seven days after operation. 
Another three groups (n=6) of animals were used to compare anastomotic collagen 
synthetic capacity, measured ex vivo in intestinal expiants by the incorporation of proline 
into collagenase-digestible protein, in control rats or rats receiving 5-FU or 5-FU plus 
levamisole. On the third postoperative day, the average anastomotic bursting pressure in 
the 5-FU/levamisole group was reduced by 36% as compared to the control group, both in 
ileum (p=0.02) and in colon (p=0.01). Values in the other groups were similar to those in 
the control group. Anastomotic breaking strength was significantly (p<0.025) lowered in 
the ileum from the levamisole group at both days three and seven. Anastomotic collagen 
synthetic capacity was strongly reduced in the 5-FU and 5-FU/levamisole groups. 
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However, there was no significant difference between the control group and the four 
experimental groups with regard to anastomotic hydroxyproline concentration and content, 
either three or seven days after operation. Thus, limited use of levamisole, alone or in 
combination with intraperitoneal 5-FU, may compromise intestinal healing. Leucovorin has 
no such effect. 
Experiments into the effects of a three day postoperative course of interferon-α and 
interferon-α plus 5-FU on early healing of intestinal anastomoses are described in chapter 
4. Four groups (n=26 each) of rats underwent resection and anastomosis of both ileum 
and colon: a control group and three groups receiving intraperitoneal 5-FU, interferon-α (2 
χ 104 U/kg body weight) or both on the day of surgery and the next two days. Animals 
were killed three or seven days (n=10 each) after operation in order to measure 
anastomotic strength and hydroxyproline content. The remaining 6 animals in each group 
were used to study anastomotic collagen synthetic capacity at day 3. Three days after 
operation, ileal anastomotic bursting pressure was lowered by 37% in the 5-FU/interferon-
α group (P=0.0104). At day 7 day, anastomotic breaking strength was reduced 
significantly in ileum (P=0.0221) and colon (P=0.0054) of the 5-FU/interferon-a group and 
in colon of the interferon-α group (P=0.00221). Collagen synthetic capacity was strongly 
suppressed by 5-FU but not by interferon-α. However, no differences in anastomotic 
hydroxyproline content were observed between groups at both days 3 and 7. Thus, 
postoperative use of interferon-α, in particular in combination with 5-FU, may be 
detrimental to anastomotic repair in the intestine. 
In chapter 5 we examined the effects of a more extended course (7 days) of post­
operative 5-FU and explored ways to promote repair under these conditions. 
We randomly assigned the animals to groups (n=10) receiving placebo, daily 5-FU (20 
mg/kg body weight intraperitoneally), daily 5-FU plus vitamin A (5000 I U/kg body weight 
orally), daily 5-FU plus interieukin-2 (IL-2; 2 χ 10e I U/kg body weight subcutaneously) or 
daily 5-FU plus granulocyte-macrophage colony-stimulating factor (GM-CSF; 5 μg on the 
first four days after operation only). The animals were killed on the seventh day after 
operation. Another three groups of animals (n=6 each) were used to measure anastomotic 
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collagen synthesis on the fourth day after surgery in rats receiving placebo, 5-FU or 5-FU 
plus vitamin A. Administration of 5-FU alone decreased anastomotic breaking strength by 
more than 40% and caused a shift in bursting site from outside to within the suture line. It 
also lowered anastomotic hydroxyproline content. The capacity for collagen synthesis, 
which was greatly enhanced in four-days old anastomoses from the control group, was 
significantly (p<0.05) and specifically reduced. Concomitant administration of vitamin A 
resulted in restoration of strength and hydroxyproline content, particularly in the ileum. IL-2 
and GM-CSF did not improve 5-FU-suppressed repair: both wound strength and collagen 
content were similar in the 5-FU, 5-FU/IL-2 and 5-FU/GM-CSF groups. 
Thus, intraperitoneal 5-FU, delivered from the day of operation onwards, severely reduces 
anastomotic strength at the end of the first postoperative week. This negative effect may 
be prevented by oral vitamin A. 
The studies described above indicate that anastomotic healing in the intestine can be 
compromised by the immediate postoperative administration of 5-FU and levamisole. 
Since fibroblast functions are crucial to healing, we investigated the effects of 
(combinations of) both drugs on proliferation and collagen synthesis of rat skin fibroblasts 
in vitro (chapter 6). Proliferation was measured by cellular [3H]thymidine uptake and 
collagen synthesis by [3H]proline incorporation into collagenase-digestible protein. 5-
Fluorouracil strongly and significantly (p<0.05) reduced DNA synthesis in actively dividing 
cells and collagen synthesis in non-dividing cells in concentrations of 1 μΜ upwards. The 
latter effect was not specific for collagen since total protein production was affected 
similarly. Both effects depended on the time of exposure to drugs. Levamisole also 
inhibited fibroblast proliferation dose-dependently, though less effectively than 5-
fluorouracil: 50% inhibition was observed at approximately 0.1 mM. Collagen synthesis 
remained unaffected by levamisole. If levamisole was added together with a low (0.1 μΜ) 
concentration of 5-fluorouracil, which in itself did not decrease thymidine incorporation, its 
anti-proliferative effects became apparent at concentrations as low as 1 μΜ. A similar 
phenomenon, though at much higher concentration, was noted on fibroblast collagen 
synthesis. These results indicate that levamisole potentiates 5-fluorouracil effects in 
fibroblast cultures and that direct effects of these drugs, alone or in combination, on 
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fibroblast proliferation and collagen synthesis may be responsible for their negative 
influence on wound repair. 
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SAMENVATTING 
Ondanks het feit dat chirurgie de enige curatieve mogelijkheid is om het coloréetele 
carcinoom te behandelen, is de 5 jaars overleving teleurstellend laag. Adjuvante 
chemotherapie kan de prognose, in het bijzonder die van patiënten met 
lymfkliermetastasen, verbeteren. Tot nu toe vormt 5-fluorouracil (5-FU) de basis van de 
chemotherapeutische behandeling van het colorectal carcinoom. Vele inspanningen, 
zowel pre-klinisch als klinisch, zijn er op gericht om de effectiviteit van 5-FU, bijvoorbeeld 
door biochemische modulatie, te verbeteren. Ook de dosering, het moment van toediening 
en de manier waarop het 5-FU wordt toegediend, blijven onderwerpen van veel discussie. 
Er zijn echter goede redenen om de chemotherapie direct na operatie te beginnen. Als 
gevolg hiervan is er een toenemende interesse voor de toediening van 5-FU in de peri-
operatieve periode. Het is daarom ook noodzakelijk om de potentiële negatieve effecten 
van 5-FU op de genezing van darmnaden te onderzoeken. 
Dit proefschrift beschrijft de effecten van регі-operatief toediening van 5-FU op de 
genezing van darmnaden in zowel het ileum als het colon, en exploreert wegen om de 
negatieve effecten van 5-FU te voorkomen. Bovendien worden experimenten beschreven, 
die proberen te onderzoeken in welke mate geneesmiddelen, zoals leucovorin, levamisole 
en Interferon-α (welke mogelijk de 5-FU anti-tumor activiteit versterken), de negatieve 
effecten van 5-FU op de darmnaadgenezing vergroten. 
Voor dit doel hebben wij een experimenteel ratmodel gebruikt, waarin de 
darmnaadgenezing wordt bestudeerd in de eerste week na operatie, wanneer de 
wondsterkte nog relatief laag is en waarbij vermindering van wondgenezing aanleiding 
kan geven tot een dehiscence van de darmnaad. Parameters voor wondgenezing zijn: de 
sterkte van de naad, het collageengehalte in de darmnaad en de collageen synthetische 
capaciteit van de darmnaad. 
Hoofdstuk 1 geeft een overzicht van de relevante literatuur. Incident«, pathologie en 
chirurgische behandeling van het coloréetele carcinoom worden kort besproken, gevolgd 
door een kort overzicht van adjuvante chemotherapie. Omdat 5-FU de hoeksteen van de 
adjuvante chemotherapeutische behandeling is, wordt aandacht besteed aan het 
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metabolisme en de mogelijkheden van biochemische modulatie. Vervolgens worden de 
algemene mechanismen van wondgenezing besproken. Het belang van het 
collageenmetabolisme voor het herstel van de wondsterkte wordt benadrukt. In het laatste 
gedeelte wordt specifiek ingegaan op de wondgenezing van de darm en de parameters 
welke nodig zijn om in een experimenteel model de genezing van darmnaden te 
bestuderen. 
Hoofdstuk 2 beschrijft de gevolgen van direct post-operatief toegediende 5-FU op de 
genezing van darmnaden van de rat. De potentiële verschillen tussen intraveneuze en 
intraperitoneale toediening van 5-FU zijn onderzocht, omdat locale (intraperitoneale) 
toediening van 5-FU een ander effect zou kunnen opleveren dan de systemische 
toediening. Drie groepen ratten (elk n=20, een controle groep en twee experimentele 
groepen) ondergingen een resectie en anastomose van zowel het ileum als het colon. 5-
FU (in een dosis van 20 mg per kg lichaamsgewicht) werd oftewel intraveneus oftewel 
intraperitoneaal toegediend, direct na operatie en op dag 1 en op dag 2 na operatie. De 
darmnaadgenezing werd op de 3e en 7e postoperatieve dag geëvalueerd. 
Toediening van 5-FU resulteerde in een verminderd aantal circulerende leucocyten. De 
naadsterkte was echter niet significant verzwakt, noch op dag 3 noch op dag 7. Het 
hydroxyprolinegehalte (als een maat voor de hoeveelheid collageen) van de darmnaad in 
beide experimentele groepen was eveneens onveranderd ten opzichte van dat in de 
controlegroep. Er was ook geen verschil tussen de groepen welke 5-FU intraveneus of 
intraperitoneaal toegediend kregen. 
Deze resultaten suggereren dat een beperkt gebruik van 5-FU gedurende of onmiddellijk 
na operatie niet noodzakelijkerwijs de vroege darmnaadgenezing verslechtert. 
Hoofdstuk 3 beschrijft een onderzoek, dat is verricht om na te gaan of toediening van 5-
FU in combinatie met leucovorine of levamisol zou resulteren in een negatief effect op de 
darmnaadgenezing. 
Vijf groepen (elk n=20) ratten ondergingen een resectie en anastomose van zowel het 
ileum als het colon: een controle groep en vier experimentele groepen die respectievelijk 
intraperitoneaal 5-FU of 5-FU + leucovorine (10 mg/kg lichaamsgewicht intraveneus) of 5-
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FU + levamisol (5mg/kg lichaamsgewicht oraal) of alleen levamisol kregen toegediend, op 
de dag van operatie en de volgende twee dagen. De ratten werden op 3 of 7 dagen na 
operatie opgeofferd ter bepaling van naadsterkte en hydroxyprolinegehalte. Als parameter 
voor de sterkte van de naad werden achtereenvolgens de 'barstdruk', als een maat voor 
de weerstand tegen intraluminale druk, en de 'treksterkte', als een maat voor de 
weerstand tegen longitudinale krachten, gemeten. Drie andere groepen (elk n=6) ratten 
werden gebruikt om de collageensynthese in de darmnaad te meten. Deze ex vivo 
procedure is gebaseerd op het meten van de inbouw van radioactief proline in 
collagenase-gevoelig eiwit door weefselexplantaten. De synthese werd bepaald in een 
controle groep, een 5-FU groep en een 5-FU + levamisol groep op de derde dag na 
operatie. Op de derde postoperatieve dag was de barstdruk van de naad in de 5-FU + 
levamisol groep verminderd met 36%, vergeleken met de controle groep, zowel in het 
ileum als in het colon. De barstdrukwaarden in de ander groepen waren vergelijkbaar met 
die van de controle groep. De treksterke van de darmnaad was significant verlaagd in het 
ileum van de levamisol groep op zowel 3 als 7 dagen na operatie. De collageensynthese 
in de darmnaad was sterk verlaagd in zowel de 5-FU groep als in de 5-FU + levamisol 
groep. Er was geen significant verschil tussen de controle groep en de andere vier 
experimentele groepen met betrekking tot het hydroxyproline gehalte van de darmnaad 
zowel op 3 als 7 dagen na operatie. 
Dus beperkt gebruik van levamisol, alleen of in combinatie met intraperitoneaal 5-FU kan 
de darmnaadgenezing verslechteren. Leucovorin heeft dit effect niet. 
In hoofdstuk 4 komen experimenten aan de orde, die onderzoeken wat de effecten op de 
darmnaadgenezing zijn van toediening van interferon-α of interferon-α + 5-FU gedurende 
de eerste 3 dagen na operatie. Vier groepen (elk n=26) ratten ondergingen resectie en 
anastomose van zowel het ileum als colon: een controle groep en drie groepen, die 
respectievelijk intraperitoneaal 5-FU, interferon-α (rat recombinant: 2x104 U/kg 
lichaamsgewicht intraperitoneaal) of 5-FU + interferon-α kregen toegediend op de dag van 
de operatie en de volgende twee dagen. De ratten werden op 3 of 7 dagen (n=10) na 
operatie opgeofferd om de naadsterkte en het hydroxyprolinegehalte te meten. De zes 
overgebleven ratten in elke groep werden gebruikt om de collageensynthese in de 
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darmnaad te meten, drie dagen na operatie. Drie dagen na operatie was de barstdruk in 
het ileum verminderd met 37% in de 5-FU + interferon-α groep. Op dag 7 was de 
treksterkte significant verminderd in het ileum (p=0.02) en in het colon (p=0.005) van de 5-
FU/interferon-a groep en in het colon van de interferon-α groep (p=0.002). De 
collageensynthese werd sterk onderdrukt door 5-FU maar niet door interferon-α. Er 
werden echter geen verschillen in het hydroxyprolinegehalte van de darmnaad gevonden 
tussen de groepen onderling, noch op dag 3 noch op dag 7 . 
Wij concluderen dat postoperatief gebruik van interferon-α, in het bijzonder in combinatie 
met 5-FU, de darmnaadgenezing kan verslechteren. 
In hoofdstuk 5 wordt het onderzoek beschreven naar de effecten van langduriger 
toediening van postoperatief 5-FU. Tevens hebben we geprobeerd om de verslechterde 
darmnaadgenezing, welke onder deze omstandigheden werd waargenomen, te 
verbeteren. 
De ratten werden willekeurig verdeeld over 5 groepen (n=10). Ze kregen dagelijks 
placebo, dagelijks 5-FU (20mg/kg lichaamsgewicht intraperitoneaal), dagelijk 5-FU + 
vitamine A (5000 IU/kg lichaamsgewicht oraal), dagelijks 5-FU + interleukine-2 (IL-2:2 χ 
10e IU/kg lichaamsgewicht subcutaan) of dagelijks 5-FU + granulocyt macrofaag kolonie 
stimulerende factor (GM-CSF; 5μg per keer op de eerste vier dagen na operatie) 
toegediend. De ratten werden op de 7e dag na operatie opgeofferd. Drie andere groepen 
ratten (n=6) werden gebruikt om de collageensynthese van de darmnaad op de vierde 
dag na operatie te meten. Deze ratten ontvingen placebo, 5-FU of 5-FU + vitamine A. 
Toediening van 5-FU alleen verminderde de treksterkte met meer dan 40% en 
veroorzaakte een verschuiving van de barstplaats van buiten de naad naar het eigenlijke 
wondgebied (een week na operatie is de barstdruk van de naad normaal gesproken altijd 
hoger dan die van de dann buiten het wondgebied'. de 'barstplaats' ligt dan ook buiten de 
naad). Ook het hydroxyprolinegehalte van de darmnaad nam sterk af. De 
collageensynthese, die duidelijk toenam in vier dagen oude anastomoses in de controle 
groep, werd in de 5-FU groep sterk onderdrukt. 
Gelijktijdige toediening van vitamine A en 5-FU resulteerde in een verbetering van de 
naadsterkte en het hydroxyprolinegehalte, met name in het ileum. IL-2 en GM-CSF 
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verbeterde de door 5-FU geremde darmnaadgenezing niet. Zowel naadsterkte als 
collageengehalte waren gelijk in de 5-FU, 5-FU + IL-2 en 5-FU + GM-CSF groepen. 
Deze resultaten geven aan dat 5-FU, indien dagelijks intraperitoneaal toegediend vanaf 
de dag van operatie, de naadsterkte aan het einde van de eerste postoperatieve week 
sterk verlaagt. Dit negatieve effect kan worden voorkomen door orale toediening van 
vitamine A. 
De hierboven beschreven studies geven onder andere aan dat de darmnaadgenezing kan 
verslechteren bij directe postoperatieve toediening van 5-FU en levamisol. Omdat 
fibroblasten cruciaal zijn voor de wondgenezing, hebben wij de effecten van beide 
geneesmiddelen onderzocht op de proliferatie en collageensynthese van rattenhuid fibro­
blasten in vitro. De resultaten zijn beschreven in hoofdstuk 6. Proliferatie werd gemeten 
aan de opname van [3H]thymidine in de cellen en collageensynthese werd gemeten aan 
de [3H]proline incorporatie in collagenase-oplosbaar eiwit. 5-FU vermindert sterk en 
significant (p<0.05) de DNA synthese in actief delende cellen en de collageensynthese in 
niet-delende cellen in concentraties van 1 μΜ en hoger. Het laatste effect was niet 
specifiek voor collageen omdat de synthese van niet-collagene eiwitten op gelijke wijze 
was aangedaan. Beide effecten waren afhankelijk van de incubatieduur in aanwezigheid 
van de medicatie. Levamisol vermindert eveneens dosis-afhankelijk de 
fibroblastproliferatie, alhoewel minder duidelijk dan 5-fluorouracil: 50% remming werd 
vastgesteld bij ongeveer 0,1 mM. De collageensynthese werd niet beïnvloed door 
levamisol. Wanneer de levamisol werd toegediend samen met een lage concentratie (0,1 
μΜ) 5-FU, die op zich de thymidine incorporatie niet vermindert, werden de anti-
proliferatieve effecten reeds zichtbaar bij concentraties in de orde van 1 μΜ. Een 
vergelijkbaar fenomeen werd, echter bij hogere concentraties, waargenomen voor de 
fibroblast collageensynthese. 
Deze resultaten suggereren dat levamisol de 5-FU effecten potentieert in fibroblast 
culturen en dat directe effecten van deze medicaties, alleen of in combinatie, op fibroblast 
proliferatie en collageen synthese verantwoordelijk zouden kunnen zijn voor de negatieve 
effecten op wondgenezing. 
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Stellingen 
1. Kortdurende toediening van 5-fluorouracil onmiddellijk na operatie, hetzij 
intraveneus hetzij intraperitoneaal, verslechtert de darmnaadgenezing niet. 
2. Langdurige toediening van 5-fluorouracil vanaf de dag van operatie ver­
slechtert de darmnaadgenezing. 
3. Kortdurende toediening van een combinatie van 5-fluorouracil en levamisol 
verslechtert de darmnaadgenezing. 
4. Kortdurende toediening van een combinatie van 5-fluorouracil en leucovo-
rin verslechtert de darmnaadgenezing niet. 
5. Kortdurende toediening van een combinatie van 5-fluorouracil en interferon-σ 
verslechtert de darmnaadgenezing. 
6. Vitamine A kan de negatieve effecten op de darmnaadgenezing, die wor­
den gezien bij langdurige toediening van 5-fluorouracil, deels voorkomen. 
7. Klinisch oncologisch onderzoek zonder daarin de kwaliteit van leven te 
betrekken, is onvolledig. 
8. Het (huidige) onderzoek naar de vraag of het inzetten van een helicopter 
een toegevoegde waarde voor de traumapatiënt heeft, zal geen weten-
schappelijk gefundeerd antwoord geven. 
9. De schildwachtklier procedure bij het mammacarcinoom zal het aantal 
okselklierdissecties tot de helft reduceren. 
10. Darmvoorbereiding bij colonchirurgie is zinloos. 
11. Een proefschrift is meer dan een aantal ingebonden artikelen. 
12. Om te komen tot een goed functionerende medische staf is harmoniseren 
van inkomens (d.w.z. geen onverklaarbare inkomensverschillen) noodzake-
lijk 
13. Het SNIFO denken (Staat Niet In mijn Functie Omschrijving) zou in het 
bijzonder in ziekenhuizen moeten worden vermeden. 
14. Dat een laag voorhoofd noodzakelijk is om de opleiding tot chirurg succes-
vol afte ronden, kan door onderzoek niet worden bevestigd. 


